

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5033727

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
MEDICAL RESEARCH COUNCIL	04/01/2018

RECEIVING PARTY DATA

Name:	UNITED KINGDOM RESEARCH AND INNOVATION
Street Address:	POLARIS HOUSE
City:	SWINDON
State/Country:	UNITED KINGDOM
Postal Code:	SN2 1FL

PROPERTY NUMBERS Total: 162

Property Type	Number
Application Number:	09493661
Application Number:	08235705
Application Number:	08407620
Application Number:	10290252
Application Number:	12127237
Application Number:	07971857
Application Number:	09726219
Application Number:	09169673
Application Number:	09196522
Application Number:	08484893
Application Number:	10803622
Application Number:	09464122
Application Number:	11518094
Application Number:	13733473
Application Number:	10263984
Application Number:	10860750
Application Number:	10861930
Application Number:	11820903
Application Number:	08943667
Application Number:	10689576

PATENT

Property Type	Number
Application Number:	12012763
Application Number:	10190012
Application Number:	09424488
Application Number:	11515369
Application Number:	10853437
Application Number:	08913915
Application Number:	09646353
Application Number:	09424487
Application Number:	11486962
Application Number:	10832735
Application Number:	11514671
Application Number:	11514850
Application Number:	10146505
Application Number:	09896915
Application Number:	11820165
Application Number:	09936170
Application Number:	12533614
Application Number:	09936975
Application Number:	09614679
Application Number:	10387387
Application Number:	10198677
Application Number:	09953814
Application Number:	10771257
Application Number:	12694071
Application Number:	12079834
Application Number:	12587432
Application Number:	10866392
Application Number:	10844720
Application Number:	13020607
Application Number:	09904779
Application Number:	09953807
Application Number:	10985321
Application Number:	12911292
Application Number:	13606696
Application Number:	12690577
Application Number:	11417449
Application Number:	10552110
Application Number:	11238257

Property Type	Number
Application Number:	15331445
Application Number:	15855612
Application Number:	11238258
Application Number:	13208614
Application Number:	13527342
Application Number:	12538392
Application Number:	10733532
Application Number:	11665145
Application Number:	15012209
Application Number:	15588210
Application Number:	13692615
Application Number:	10961695
Application Number:	11665030
Application Number:	11727935
Application Number:	11507961
Application Number:	12440374
Application Number:	12143886
Application Number:	14859596
Application Number:	13769655
Application Number:	12732909
Application Number:	14716568
Application Number:	12302317
Application Number:	12026861
Application Number:	12596053
Application Number:	12172821
Application Number:	12996307
Application Number:	12536014
Application Number:	13121898
PCT Number:	US2016012209
Application Number:	12310048
Application Number:	12553932
Application Number:	12244715
Application Number:	14056559
Application Number:	13262123
Application Number:	15463964
Application Number:	12172850
Application Number:	13262187
Application Number:	13376068

Property Type	Number
Application Number:	15288934
Application Number:	13636958
Application Number:	15033750
Application Number:	13509035
Application Number:	12833548
Application Number:	13695377
Application Number:	14872814
Application Number:	13981433
Application Number:	14395429
Application Number:	14760350
Application Number:	14240832
Application Number:	15117784
Application Number:	15022041
Application Number:	14345138
Application Number:	14346284
Application Number:	14782654
Application Number:	14782650
Application Number:	14402061
Application Number:	14401725
Application Number:	14373292
Application Number:	14424332
Application Number:	14401803
Application Number:	14402034
Application Number:	14653734
Application Number:	15507676
Application Number:	15119071
Application Number:	15747117
Application Number:	14768740
Application Number:	14911718
Application Number:	14911723
Application Number:	14776908
Application Number:	15037941
Application Number:	15322939
Application Number:	15124632
Application Number:	15521103
Application Number:	15567419
Application Number:	11032149
Application Number:	13359348

Property Type	Number
Application Number:	09874198
Application Number:	14031377
Application Number:	09874238
Application Number:	15227479
Application Number:	60042678
Application Number:	09722364
Application Number:	08470031
Application Number:	07941762
Application Number:	07933959
Application Number:	07933958
Application Number:	07796805
Application Number:	07941761
Application Number:	09726653
Application Number:	10910463
Application Number:	10400017
Application Number:	11500162
Application Number:	09139762
Application Number:	10397930
Application Number:	10309578
Application Number:	08793408
Application Number:	10033129
Application Number:	09851271
Application Number:	09732348
Application Number:	13693356
Application Number:	09726649
Application Number:	62307687
Application Number:	29531136
Application Number:	29626922

CORRESPONDENCE DATA

Fax Number: (312)222-0818

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (312) 222-0800

Email: chiipdocket@michaelbest.com

Correspondent Name: GREGORY J. HARTWIG

Address Line 1: 444 W. LAKE STREET

Address Line 2: SUITE 3200

Address Line 4: CHICAGO, ILLINOIS 60606

ATTORNEY DOCKET NUMBER:	065435-9000-US00
NAME OF SUBMITTER:	GREGORY J. HARTWIG
SIGNATURE:	/Gregory J. Hartwig/
DATE SIGNED:	07/02/2018

Total Attachments: 81

source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page1.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page2.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page3.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page4.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page5.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page6.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page7.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page8.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page9.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page10.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page11.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page12.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page13.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page14.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page15.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page16.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page17.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page18.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page19.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page20.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page21.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page22.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page23.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page24.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page25.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page26.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page27.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page28.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page29.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page30.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page31.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page32.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page33.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page34.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page35.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page36.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page37.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page38.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page39.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page40.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page41.tif
source=065435-9000-US00-ASSIGNMENT-MRC-TO-UKRI-07-02-18#page42.tif

Higher Education and Research Act 2017 (United Kingdom Research and Innovation) Property Transfer Scheme 2018

Whereas it is the intention of the Secretary of State to cause the Research Councils as listed in section 109 of the Higher Education and Research Act 2017 to cease to exist following: (i) the completion of their final accounts; and (ii) the Research Councils having taken any such steps as is necessary to give effect to the transfer of all property, rights and liabilities in accordance with this Property Transfer Scheme to United Kingdom Research and Innovation;

And whereas from and including the date on which this Property Transfer Scheme takes effect, United Kingdom Research and Innovation is to exercise its statutory research and innovation functions pursuant to section 93 of the Higher Education and Research Act 2017 and the Research Councils are to cease to exercise their research and innovation functions;

Now the Secretary of State, in exercise of the powers conferred by section 115 and Schedule 10(1) and 10(2) of the Higher Education and Research Act 2017, makes this Property Transfer Scheme in connection with the establishment of United Kingdom Research and Innovation.

Interpretation

1. In this Transfer Scheme-

“the Act” means the Higher Education and Research Act 2017;

“CEO” means the Chief Executive Officer of UKRI;

“HEFCE” means the Higher Education Funding Council for England, a body corporate established pursuant to section 62(1) of the Further and Higher Education Act 1992;

“intellectual property rights” means patents, utility models, rights to inventions, copyright and neighbouring and related rights, trade marks and service marks, business names and domain names, rights in get-up and trade dress, goodwill and the right to sue for passing off or unfair competition, rights in designs, database rights, rights to use, and protect the confidentiality of, confidential information (including know-how and trade secrets) and all other intellectual property rights, in each case whether registered or unregistered and including all applications and rights to apply for and be granted, renewals or extensions of, and rights to claim priority from, such rights and all similar or equivalent rights or forms of protection which subsist or will subsist now or in the future in any part of the world;

“land” includes all freeholds and heritable interests, leases, subleases, licences, customary rights, easements, servitudes, quasi easements and contracts relating to such land and (in addition to land) buildings, structures and works in, on, under or over such land, formations, earthworks, culverts, drains, means of enclosure, retaining walls and land covered by water, together with loose and fixed plant, equipment and machinery and mines and minerals;

“records” includes material in whatever form or medium which conveys, or is capable of conveying information inclusive of data;

“research councils” means the research councils listed in section 109(1) of the Act;

“symbolic property” has the meaning given to it in section 109(4) of the Act;

“UKRI” means United Kingdom Research and Innovation, a body corporate established pursuant to section 91(1) of the Act; and

other words and expressions used in this Order have the same meanings as in the Act.

Transfer Date

2. The transfer date is 1 April 2018.

Transfer of property, rights and liabilities of the research councils and the Higher Education Funding Council for England

3. Subject to paragraph 5 below, on the transfer date all property (including symbolic property), rights and liabilities of the research councils are transferred to UKRI.
4. The property (including symbolic property), rights and liabilities transferred to UKRI under paragraph 3 include without limitation:
 - a. all property, rights and liabilities of each research council in or relating to the land within England and Wales listed in Schedule 1;
 - b. all property, rights and liabilities of each research council in or relating to the land within Scotland listed in Schedule 2;
 - c. all property, rights and liabilities of each research council in or relating to any other land in which immediately before the transfer date that research council has any property, rights or liabilities;
 - d. the MRC Pension Scheme governed by the Definitive Trust Deed of 20 December 2011;
 - e. all intellectual property rights; and
 - f. all information, data and records.
5. Rights or liabilities under or in connection with a contract of employment with any of the research councils are not transferred to UKRI under this Transfer Scheme.
6. On the transfer date, the property, rights and liabilities of HEFCE as listed in Schedule 3 transfer to UKRI.
7. Rights or liabilities under or in connection with a contract of employment with HEFCE (as transferred to UKRI under this Transfer Scheme) are not transferred to UKRI under this Transfer Scheme.

Transitional, incidental and supplementary provisions

8. Anything done (or having effect as if done) before the transfer date by or in relation to the research councils and HEFCE as transferred to UKRI by this Transfer Scheme, has effect on and after that date as if done by or in relation to UKRI.
9. Anything (including legal proceedings) which, before the transfer date is in the process of being done by, on behalf of, or in relation to the research councils and HEFCE as transferred to UKRI by this Transfer Scheme may be continued on and after that date as if done by, on behalf of, or in relation to UKRI.
10. Any reference to the research councils and HEFCE as transferred to UKRI by this Transfer Scheme in any contract or agreement (whether written or not), instrument or other document has effect on and after the transfer date as a reference to UKRI in so far as it relates to anything transferred to UKRI.
11. This Transfer Scheme does not affect the validity of anything done (or having effect as if done) by or in relation to the research councils and HEFCE as transferred to UKRI by this Transfer Scheme before the transfer date.
12. Any transfer provided for by this scheme has effect:

- a. regardless of anything (of whatever nature) that would otherwise prevent, restrict or penalise the transfer of any of that property or those rights or liabilities;
 - b. without any instrument or other formality being required;
 - c. irrespective of any requirement for consent that would otherwise apply (whether arising under any enactment, instrument, agreement or otherwise); and
 - d. whether or not they would otherwise be capable of being transferred.
13. A certificate issued by, or on behalf of, the Secretary of State will be conclusive evidence that any property (including symbolic property), rights and/or liabilities (as appropriate) has transferred to UKRI.
 14. The Secretary of State, or another acting on their behalf, may execute any document or perform any act which is required to transfer any property (including symbolic property), rights and liabilities of the research councils and any property, rights and liabilities of HEFCE which are listed in Schedule 3.
 15. Any rights relating to a contract or agreement (whether written or not), instrument or other document transferred by virtue of any provision of this Transfer Scheme which were enforceable by or against the transferor immediately before the transfer date are, on and following the transfer date, to be enforceable by or against the transferee.
 16. Any liabilities relating to a contract or agreement (whether written or not), instrument or other document transferred by virtue of any provision of this Transfer Scheme which were enforceable by or against the transferor immediately before the transfer date are, on and following the transfer date, to be enforceable by or against the transferee.
 17. No right to terminate or vary a contract or agreement (whether written or not), instrument or other document is to operate or become exercisable, and no provision of any contract or agreement (whether written or not), instrument or other document is to operate or become exercisable or contravened, by reason of the transfer made by this Transfer Scheme.
 18. Where the rights and liabilities under a contract or agreement (whether written or not), instrument or other document are transferred by virtue of any provision of this Transfer Scheme on the transfer date, from a transferor to a transferee, that contract or agreement (whether written or not), instrument or other document is to continue to have effect as if it was originally entered into or agreed by the transferee.
 19. No right to terminate the membership of a body corporate is to operate or become exercisable, and no provision of a body corporate's constitution is to operate or become exercisable or be contravened, by reason of the transfer made by this Transfer Scheme.
 20. No right of reverter, right of pre-emption, right of forfeiture, right of re-entry, right to compensation, option or similar right affecting any land or other property or right is to operate or become exercisable as a result of any transfer of land or other property or right by virtue of this Transfer Scheme (whether or not any consent required to the transfer has been obtained).

Modifications

21. This Transfer Scheme may be modified by the Secretary of State with UKRI's written agreement on or after the transfer date and any such modifications may have effect from the transfer date.

Name: SHARON CUI

Signed: 

Date: 23/03/18

Department for Business, Energy and Industrial Strategy, for and on behalf of the Secretary of State

TO ALL TO WHOM THESE PRESENTS SHALL COME, I **EDWARD GARDINER** of the City of London, England **NOTARY PUBLIC** by royal authority duly admitted, sworn and holding a faculty to practise throughout England and Wales, DO HEREBY CERTIFY that the common seal of **MEDICAL RESEARCH COUNCIL**, a body incorporated by Royal Charter dated 1 April 1920 whose Royal Charter number is RC000346 (hereinafter called the "Council"), was affixed at foot of the instrument hereunto annexed in the manner prescribed by the regulations of the Council in my presence and in that of **DONALD HOOD BRYDON** and **FIONA MARY WATT**, authorised signatories of the Council, who signed in my presence at foot of the said instrument as such authorised signatories and as witnesses to the affixing of the said common seal, and did then deliver the said instrument as and for the act and deed of the Council;

AND I DO FURTHER CERTIFY that the common seal of **UNITED KINGDOM RESEARCH AND INNOVATION**, (also known as UK Research and Innovation) (hereinafter called "UKRI") a body corporate established pursuant to section 91 of the Higher Education and Research Act 2017 was affixed at foot of the said instrument in the manner prescribed by the regulations of UKRI in my presence and in that of **IAN PETER KENYON**, member and authorised signatory of UKRI, who signed in my presence at foot of the said instrument as such authorised signatory and as witness to the affixing of the said common seal, and did then deliver the said instrument as and for the act and deed of UKRI;

AND that the said instrument being so sealed, signed and delivered is duly executed as a deed and binds the said **MEDICAL RESEARCH COUNCIL** and the said **UNITED KINGDOM RESEARCH AND INNOVATION** in accordance with the provisions of the law of England and Wales.



Regulated by the Faculty Office of the Archbishop of Canterbury

Bankside House, 107 Leadenhall Street, London EC3A 4AF

Tel 020 7623 9477 Fax 020 7626 1504

Email notary@cheeswrights.co.uk

DX 627 / London City EC3 www.cheeswrights.co.uk


Canary Wharf office Tel 020 7712 0000

PATENT

REEL: 046469 FRAME: 0119

IN FAITH AND TESTIMONY WHEREOF I the said notary have
subscribed my name and set and affixed my seal of office in
London, England this twenty sixth day of April in the year two
thousand and eighteen.

Felicit Caroline



This deed is dated 26 April 2018

PARTIES

- (1) **Medical Research Council** a body incorporated by Royal Charter dated 1 April 1920 whose Royal Charter number is RC000346 (the "**Council**")
- (2) **United Kingdom Research and Innovation** (also known as UK Research and Innovation) a body corporate established pursuant to section 91 of the Higher Education and Research Act 2017 whose address is Polaris House, North Star Avenue, Swindon, SN2 1FL ("**UKRI**")

BACKGROUND

- (A) Pursuant to Section 115 and Schedule 10 of the Higher Education and Research Act 2017 (the "**Act**"), the Secretary of State was provided with the right to make a property transfer scheme for the purpose of transferring all of the Council's property, rights or liabilities to UKRI.
- (B) Such a transfer scheme has been made with an effective date of 1 April 2018 (the "**Transfer Scheme**"). The property, rights and liabilities transferred under the Transfer Scheme includes all Intellectual Property Rights and Contracts (each as defined below) of the Council.
- (C) To the extent not otherwise transferred from the Council to UKRI (including without limitation under the Transfer Scheme), the parties now (a) assign the Council's Assigned Rights (defined below), and (b) deal with the Contracts (defined below), each as set out in this deed.

AGREED TERMS

1 INTERPRETATION

The following definitions and rules of interpretation apply in this agreement.

1.1 Definitions:

Assigned Rights: all Intellectual Property Rights owned by the Council as at 23:59:59 on 31 March 2018 including the Patents, the Trade Marks and the Registered Designs.

Contracts: all contracts to which the Council is a party as at 23:59:59 on 31 March 2018.

Effective Date: 00:00:00 on 01 April 2018.

Intellectual Property Rights: patents, utility models, rights to inventions, copyright and neighbouring and related rights, trade marks and service marks, business names

and domain names, rights in get-up and trade dress, goodwill and the right to sue for passing off or unfair competition, rights in designs, database rights, rights to use, and protect the confidentiality of, confidential information (including know-how and trade secrets) and all other intellectual property rights, in each case whether registered or unregistered and including all applications and rights to apply for and be granted, renewals or extensions of, and rights to claim priority from, such rights and all similar or equivalent rights or forms of protection which subsist or will subsist now or in the future in any part of the world.

Patents: the patents and the applications short particulars of which are set out in Schedule 1.

Registered Designs: the registered designs and the applications short particulars of which are set out in Schedule 3.

Trade Marks: the registered trade marks and the applications short particulars of which are set out in Schedule 2.

- 1.2 Clause, Schedule and paragraph headings shall not affect the interpretation of this agreement.
- 1.3 A person includes a natural person, corporate or unincorporated body (whether or not having separate legal personality).
- 1.4 The Schedules form part of this agreement and shall have effect as if set out in full in the body of this agreement. Any reference to this agreement includes the Schedules.
- 1.5 References to clauses and Schedules are to the clauses and Schedules of this agreement.
- 1.6 Unless the context otherwise requires, words in the singular shall include the plural and in the plural shall include the singular.
- 1.7 A reference to a statute or statutory provision is a reference to it as amended, extended or re-enacted from time to time.
- 1.8 A reference to a statute or statutory provision shall include all subordinate legislation made from time to time under that statute or statutory provision.
- 1.9 A reference to **writing** or **written** includes fax but not email.
- 1.10 Any words following the terms **including**, **include**, **in particular**, **for example** or any similar expression shall be construed as illustrative and shall not limit the sense of the words, description, definition, phrase or term preceding those terms.

2

ASSIGNMENT

2.1

In consideration of the sum of £1 (paid by UKRI to the Council, receipt of which the Council expressly acknowledges) and to the extent not transferred to UKRI under the Transfer Scheme (or otherwise), with effect from the Effective Date, the Council:

- (a) hereby assigns to UKRI absolutely all its right, title and interest in and to the Assigned Rights, including:
 - (i) the right to claim priority from, and absolute entitlement to any registrations granted pursuant to any of the applications comprised in the Assigned Rights;
 - (ii) all goodwill attaching to the Trade Marks and to that part of the Council's business that relates to the goods or services for which the Trade Marks are registered or used; and
 - (iii) the right to bring, make, oppose, defend, appeal proceedings, claims or actions and obtain relief (and to retain any damages recovered) in respect of any infringement, or any other cause of action arising from ownership, of any of the Assigned Rights whether occurring before, on, or after the date of this agreement; and
- (b) shall, to the extent permitted by law hold the Contracts on trust for UKRI until transferred to UKRI.

2.2

UKRI hereby accepts the assignment of the Assigned Rights from the Council on the terms set out in this agreement.

3

LICENCE

To the extent that the Assigned Rights are not transferred to UKRI (whether under the Transfer Scheme, this agreement or otherwise), the Council hereby grants UKRI a worldwide exclusive non-terminable royalty-free licence (including the right to sublicense) to use such Assigned Rights until such time as (in each case) the relevant Assigned Rights are assigned validly to UKRI.

4

FURTHER ASSURANCE AND POWER OF ATTORNEY

4.1

The Council shall, and shall use all reasonable endeavours to procure that any necessary third party shall, promptly execute and deliver such documents and perform such acts as may be required for the purpose of giving full effect to this agreement, including:

- (a) in respect of Assigned Rights (or applications to register Assigned Rights), assisting UKRI in recording UKRI as (as applicable) applicant for, or proprietor of, the Assigned Rights; and
- (b) assisting UKRI in obtaining, defending and enforcing the Assigned Rights, and assisting with any other proceedings which may be brought by or against UKRI against or by any third party relating to the Assigned Rights.

4.2 The Council appoints UKRI to be its attorney in its name and on its behalf to execute documents, use the Council's name and do all things which are necessary or desirable for UKRI to obtain for itself or its nominee the full benefit of this agreement.

4.3 This power of attorney is irrevocable and is given by way of security to secure the performance of the Council's obligations under this agreement and the proprietary interest of UKRI in the Assigned Rights and so long as such obligations of the Council remain undischarged, or UKRI has such interest, the power may not be revoked by the Council, save with the consent of UKRI.

4.4 Without prejudice to Clause 4.2, UKRI may, in any way it thinks fit and in the name and on behalf of the Council:

- (a) take any action that this agreement requires the Council to take;
- (b) perform and take the benefit of the Contracts (save to the extent that the relevant Contract prohibits it);
- (c) exercise any rights which this agreement gives to the Council; and
- (d) appoint one or more persons to act as substitute attorney(s) for the Council and to exercise such of the powers conferred by this power of attorney as UKRI thinks fit and revoke such appointment.

The Council undertakes to ratify and confirm everything that UKRI and any substitute attorney does or arranges or purports to do or arrange in good faith in exercise of any power granted under this clause.

5 COUNTERPARTS

5.1 This agreement may be executed in any number of counterparts, each of which when executed shall constitute a duplicate original, but all the counterparts shall together constitute the one agreement.

5.2 No counterpart shall be effective until each party has executed at least one counterpart.

6 **THIRD PARTY RIGHTS**

This agreement does not give rise to any rights under the Contracts (Rights of Third Parties) Act 1999 to enforce any term of this agreement.

7 **GOVERNING LAW**

This agreement and any dispute or claim (including non-contractual disputes or claims) arising out of or in connection with it or its subject matter or formation shall be governed by and construed in accordance with the law of England and Wales.

8 **JURISDICTION**

Each party irrevocably agrees that the courts of England and Wales shall have exclusive jurisdiction to settle any dispute or claim (including non-contractual disputes or claims) arising out of or in connection with this agreement or its subject matter or formation.

This document has been executed as a deed and is delivered and takes effect on the date stated at the beginning of it.

Schedule I

PATENTS

Part A - MRC Patented

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
A813/0763	Speech Synthesis	National Phase	Application	Japan	2000-015517	25/01/2000	30/09/2001	3174777
A813/0763	Speech Synthesis	National Phase	Application	United States	09/493,661	29/01/2000	06/01/2004	6,675,140
A813/0763	Speech Synthesis	National Phase	Application	Japan	1999-0020137	28/01/1999		
A813/0895	Campath-1	National Phase	Application	Germany	2001199051	10/02/1999	04/05/2005	DE10199051
A813/0895	Campath-1	National Phase	Application	United States	08/235,705	29/04/1994	08/12/1998	5,846,534
A813/0895	Campath-1	National Phase	Divisional	United States	08/407,620	21/03/1995	27/05/2003	6,569,430
A813/0930	Winter fl/Library Construction (phage)	National Phase	Application	United States	10/290,252	08/11/2002	11/12/2007	7,306,907
A813/0930	Winter fl/Library Construction (phage)	National Phase	Application	Norway	90.3059	13/11/1989		
A813/0930	Winter fl/Library Construction (phage)	National Phase	Continuation	United States	12/127,237	13/11/1989		
A813/0930	Winter fl/Library Construction (phage)	National Phase	Application	United States	07/971,857	01/08/1993		
A813/0930	Winter fl/Library Construction (phage)	National Phase	Application		903489	13/11/1989		
A813/1046	Phage Antibody Screening (McCafferty)	National Phase	Continuation	United States	09/726,219	28/11/2000	19/10/2004	6806079
A813/1046	Phage Antibody Screening (McCafferty)	National Phase	Continuation	United States	09/169,673	20/11/1998	20/06/2006	7,063,943
A813/1046	Phage Antibody Screening (McCafferty)	National Phase	Continuation	United States	09/196,522	20/11/1999	12/07/2005	6916605
A813/1046	Phage Antibody Screening (McCafferty)	National Phase	Application	United States	07/971,857	09/01/1993	19/10/1999	5,969,108
A813/1046	Phage Antibody Screening (McCafferty)	National Phase	Continuation	United States	08/484,693	07/06/1995	09/01/2001	6,172,197
A813/1046	Phage Antibody Screening (McCafferty)	National Phase	Divisional	United States	10/803,622	18/03/2004	08/06/2010	7,732,377

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
A813/1323	In Vitro Sorting Method	National Phase	Divisional	Canada	2,792,122	02/10/2012	08/09/2015	2,792,122
A813/1323	In Vitro Sorting Method	National Phase	Application	United Kingdom	9929447.2	29/06/1998	23/10/2002 11:02	2342094
A813/1323	In Vitro Sorting Method	National Phase	Application	Canada	2,295,324	29/06/1998	08/12/2012	2295324
A813/1323	In Vitro Sorting Method	National Phase	Divisional	Europe	07019329.7	02/10/2007	26/12/2012	EP1908832
A813/1323	In Vitro Sorting Method	National Phase	Application	United States	09/464,122	29/06/1998	03/12/2002	6,499,103
A813/1323	In Vitro Sorting Method	National Phase	Application	Europe	98930958.6	29/06/1998	29/09/2004	1019496
A813/1323	In Vitro Sorting Method	National Phase	Divisional	Europe	04077102.4	20/07/2004	28/03/2007	1496120
A813/1323	In Vitro Sorting Method	National Phase	Application	Australia	1998/81231	29/06/1998	15/11/2001	736836
A813/1323	In Vitro Sorting Method	National Phase	Divisional	United States	11/518,094	08/09/2006	01/09/2009 10:45	7,582,446
A813/1323	In Vitro Sorting Method	National Phase	Divisional	United States	13,733,473	03/06/2004	27/02/2016	9528106
A813/1323	In Vitro Sorting Method	National Phase	Divisional	Japan	2005-041355	29/06/1998	24/04/2009	4298255
A813/1323	In Vitro Sorting Method	National Phase	Application	Japan	2000-502169	29/06/1998	24/04/2009 13:45	4298912
A813/1323	In Vitro Sorting Method	National Phase	Divisional	United States	10,263,984	03/10/2002	21/11/2006	7,138,233
A813/1323	In Vitro Sorting Method	National Phase	Divisional	United States	10,860,750	03/10/2002	07/08/2007	7,252,943
A813/1323	In Vitro Sorting Method	National Phase	Divisional	United States	10,861,930	04/06/2004	29/12/2009	7,638,276
A813/1323	In Vitro Sorting Method	National Phase	Application	Hong Kong	08111141.7	26/06/1998		
A813/1323	In Vitro Sorting Method	National Phase	Divisional	Japan	2007-061017	09/03/2007		
A813/1323	In Vitro Sorting Method	National Phase	Divisional	United States	11,820,903	03/06/2004	05/02/2013	8367396
A813/1340	FDK1	National Phase	Application	United States	08/943,667	09/10/1997	11/05/2004	6,734,001
A813/1340	PDK1	National Phase	Continuation	United States	10,689,576	20/10/2004	18/03/2008	7,344,870
A813/1340	PDK1	National Phase	Application	Europe	98909642.5	16/03/1998	23/11/2005	0683363
A813/1340	PDK1	National Phase	Application	Canada	2284119	16/03/1998	15/06/2010	2,284,119
A813/1340	PDK1	National Phase	Application	Japan	1998-540243	16/03/1998	15/03/2006	9795535
A813/1340	PDK1	National Phase	Application	Australia	64124/98	16/03/1998	04/10/2001	734754
A813/1340	PDK1	National Phase	Divisional	United States	12/912,783	05/02/2008	30/11/2010	7,842,488
A813/1340	PDK1	National Phase	Divisional	United States	10/190,012	05/07/2002	17/04/2007	7,205,390

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
A813/1361	Nucleic Acid Binding Proteins	National Phase	Application	United States	09/424,488	26/05/1998	15/03/2005	6,866,997
A813/1361	Nucleic Acid Binding Proteins	National Phase	Application	Canada	2,290,866	26/05/1998	31/08/2010	2290866
A813/1361	Nucleic Acid Binding Proteins	National Phase	Application	Australia	75426/98	26/05/1998	26/07/2001	732017
A813/1361	Nucleic Acid Binding Proteins	National Phase	Application	Europe	98922967.9	26/05/1998	30/04/2008	0983351
A813/1361	Nucleic Acid Binding Proteins	National Phase	Application	Japan	1998-550158	26/05/1998		
A813/1361	Nucleic Acid Binding Proteins	National Phase	Continuation	United States	11/515,369	31/08/2006	20/07/2010	7,759,059
A813/1361	Nucleic Acid Binding Proteins	National Phase	Continuation	United States	10/853,437	24/05/2004	10/07/2007	7,241,574
A813/1388	Inhibitor of Tau - Tau Association	National Phase	Application	United States	08/913,915	25/03/1997	23/04/2002	6,376,205
A813/1388	Inhibitor of Tau - Tau Association	National Phase	Application	Canada	CA19962215397	25/03/1996	02/02/2008	2215397
A813/1420	Methylation	National Phase	Application	Canada	2,323,064	17/03/1999	31/05/2011	2323064
A813/1420	Methylation	National Phase	Application	Europe	99910512.5	17/03/1999	16/09/2006	1064369
A813/1420	Methylation	National Phase	Application	Australia	29449/99	17/03/1999	28/11/2002	751487
A813/1420	Methylation	National Phase	Application	United States	09/646,353	17/03/1999	20/12/2005	6,977,154
A813/1420	Methylation	National Phase	Application	New Zealand	506987	17/03/1999	12/05/2003	506987
A813/1436	Nucleic Acid Binding Proteins	National Phase	Application	Europe	88922984.6	26/05/1998	30/04/2008	0983350
A813/1438	Nucleic Acid Binding Proteins	National Phase	Application	United States	09/424,487	26/05/1998	08/06/2004	6,746,838
A813/1438	Nucleic Acid Binding Proteins	National Phase	Application	Canada	2,290,717	26/05/1998	05/01/2010	2,290,717
A813/1438	Nucleic Acid Binding Proteins	National Phase	Continuation	United States	11/486,962	26/05/1998	31/12/2013	8,617,807
A813/1438	Nucleic Acid Binding Proteins	National Phase	Continuation	United States	10/832,735	26/05/1998	10/07/2007	7,241,573
A813/1439	Nucleic Acid Binding Polypeptide Library	National Phase	Application	Europe	98922963.8	26/05/1998	13/04/2016	EP0983349
A813/1439	Nucleic Acid Binding Polypeptide Library	National Phase	Application	Australia	1998-75422	26/05/1998	13/12/2001	737756
A813/1439	Nucleic Acid Binding Polypeptide Library	National Phase	Application	Japan	2012-129566	26/05/1998	14/10/2015	JP5795749
A813/1439	Nucleic Acid Binding Polypeptide Library	National Phase	Application	Canada	2,290,720	26/05/1998	15/07/2008	2,290,720
A813/1439	Nucleic Acid Binding Polypeptide Library	National Phase	Application	United States	11/514,671	26/05/1998	20/04/2010	7,700,523

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
	Library							
A813/1439	Nucleic Acid Binding Polypeptide Library	National Phase	Application	United States	11/5/14,850	26/05/1998	31/12/2013	8,618,024
A813/1467	Method For Generating Diversity	National Phase	Divisional	Europe	09180683.6	08/10/1999	01/06/2016	2204447
A813/1467	Method For Generating Diversity	National Phase	Application	Europe	99947775.5	08/10/1999	30/12/2009 10:36	1117774
A813/1467	Method For Generating Diversity	National Phase	Application	Canada	2,346,927	08/10/1999	22/09/2009	2,346,927
A813/1467	Method For Generating Diversity	National Phase	Application	Japan	2000-576002	08/10/1999	01/05/2009 16:04	4302894
A813/1467	Method For Generating Diversity	National Phase	Application	Australia	61142/99	08/10/1999	09/12/2004	0776049
A813/1467	Method For Generating Diversity	National Phase	Continuation in Part	United States	10/146,505	15/05/2002	17/10/2006 12:06	7,122,339
A813/1467	Method For Generating Diversity	National Phase	Application	United Kingdom	9901141.3	19/01/1999		
A813/1467	Method For Generating Diversity	National Phase	Application	United Kingdom	9822104.7	09/10/1998		
A813/1467	Method For Generating Diversity	National Phase	Application	United Kingdom	9913435.5	09/06/1999		
A813/1488	Optical Sorting Method	National Phase	Divisional	Japan	2011-33216	06/01/2000	15/02/2013	5198597
A813/1488	Optical Sorting Method	National Phase	Application	Australia	18844/00	06/01/2000	12/05/2005	781217
A813/1488	Optical Sorting Method	National Phase	Application	Canada	2,357,037	06/01/2000	11/12/2012	2,357,037
A813/1488	Optical Sorting Method	National Phase	Application	Japan	2000-592409	06/01/2000	28/10/2011	4651008
A813/1488	Optical Sorting Method	National Phase	Application	United States	09/996,915	06/01/2000	26/10/2004	6,808,882
A813/1488	Optical Sorting Method	National Phase	Divisional	Europe	04077799.7	06/01/2000	07/03/2012	1522581
A813/1488	Optical Sorting Method	National Phase	Divisional	Europe	07013020.8	06/01/2000	08/08/2012	1905828
A813/1488	Optical Sorting Method	National Phase	Divisional	Australia	2004242526	06/01/2000	20/12/2007	2004242526
A813/1488	Optical Sorting Method	National Phase	Application	Europe	00900080.3	06/01/2000	11/11/2009 10:00	1141272
A813/1488	Optical Sorting Method	National Phase	Divisional	United States	11/820,155	06/01/2000	01/03/2011	7,897,341
A813/1488	Optical Sorting Method	National Phase	Divisional	Japan	2007-060980	09/03/2007		
A813/1488	Optical Sorting Method	National Phase	Application	Hong Kong	08111011.4	02/10/2008		
A813/1490	Intracellular Selection	National Phase	Application	United States	09/936,170	10/03/2000	04/08/2009	7,568,390
A813/1490	Intracellular Selection	National Phase	Application	Europe	00909465.7	10/03/2000	14/12/2011	1166121

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
A813/1490	Intracellular Selection	National Phase	Divisional	United States	12/533,614	31/07/2009 10-12	01/03/2011	7,897,347
A813/1493	Photoreleasable Compounds	National Phase	Application	United States	09/936,975	27/12/2001	20/07/2004	6,765,014
A813/1500	Quadruplexes	National Phase	Application	United States	09/614,679	12/07/2000	10/12/2002	6,492,117
A813/1545	Directed Evolution Method	National Phase	Application	Europe	01965462.3	13/09/2001	02/11/2006	1317539
A813/1545	Directed Evolution Method	National Phase	Application	Japan	2002-527309	13/09/2001	08/06/2012	5009481
A813/1545	Directed Evolution Method	National Phase	Application	United States	10/387,387	13/03/2003	07/04/2009	7,514,210
A813/1545	Directed Evolution Method	National Phase	Application	Japan	2007-190027			
A813/1545	Directed Evolution Method	National Phase	Application	Hong Kong	09102026.5	03/03/2009		
A813/1571	Linkers	National Phase	Application	Canada	2398155	19/01/2001	19/07/2011	2398155
A813/1571	Linkers	National Phase	Application	Europe	01901276.4	19/01/2001	28/02/2007	1250424
A813/1571	Linkers	National Phase	Application	Australia	2001226935	19/01/2001	19/10/2006	2001226935
A813/1571	Linkers	National Phase	Application	United Kingdom	0013102.9	30/05/2000		
A813/1571	Linkers	National Phase	Application	United Kingdom	0013104.5	30/05/2000		
A813/1571	Linkers	National Phase	Application	United Kingdom	0013103.7	30/05/2000		
A813/1571	Linkers	National Phase	Application	United States	10/196,677	19/01/2001	14/12/2010	7,851,216
A813/1571	Linkers	National Phase	Application	United Kingdom	0001582.6	24/01/2000		
A813/1585	Crystal Structure	National Phase	Application	United Kingdom	0117142.0	14/07/2001	11/11/2004	2368067
A813/1585	Crystal Structure	National Phase	Continuation in Part	United States	09/953,814	17/09/2001	18/07/2006	7,079,956
A813/1627	Process for Producing Photocleavable Corn	National Phase	Application	Europe	02701456.2	08/03/2002	18/02/2009	1377548
A813/1636	Viral Fingers	National Phase	Application	United Kingdom	0013106	30/05/2000		
A813/1636	Viral Fingers	National Phase	Application	United Kingdom	0101446.3	19/01/2001		
A813/1636	Viral Fingers	National Phase	Application	United Kingdom	0011068.4	08/05/2000		
A813/1667	Intrabodies	National Phase	Application	United States	10771,257	03/02/2004	27/10/2009	7,608,453
A813/1673	Emulsion Compositions	National Phase	Application	Europe	04078078.5	18/11/2002	05/09/2007	1518937

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
A813/1673	Emulsion Compositions	National Phase	Continuation in Part	United States	12/694,071	28/02/2010	10/04/2012	8,153,364
A813/1673	Emulsion Compositions	National Phase	Divisional	United States	12/079,834	28/03/2008	02/02/2010	7,655,435
A813/1673	Emulsion Compositions	National Phase	Application	Australia	2002339193	18/11/2002	15/05/2008	2002339193
A813/1673	Emulsion Compositions	National Phase	Application	Europe	02777570.9	18/11/2002	27/08/2008	1446504
A813/1673	Emulsion Compositions	National Phase	Application	Canada	2,467,215	18/11/2002	02/10/2012	2,467,215
A813/1673	Emulsion Compositions	National Phase	Application	Japan	2003-545810	17/05/2004	30/04/2010	4503290
A813/1673	Emulsion Compositions	National Phase	Continuation	United States	12/587,432	06/10/2009 08.57	10/04/2012	8,153,364
A813/1673	Emulsion Compositions	National Phase	Divisional	United States	10/866,392	11/06/2004	24/11/2009	7,622,280
A813/1673	Emulsion Compositions	National Phase	Application	United States	10/844,720	13/05/2004	30/09/2008	7,429,467
A813/1675	Recombinant SP-D	National Phase	Divisional	Japan	2009-272082	25/10/2002	09/05/2014	5538427
A813/1675	Recombinant SP-D	National Phase	Application	Europe	02772550.6	25/10/2002	02/10/2013	1440083
A813/1675	Recombinant SP-D	National Phase	Divisional	United States	13/020,607	25/10/2002	21/10/2014	8,865,643
A813/1678	Crystal Structure	National Phase	Application	United States	09/904,779	13/07/2001	02/08/2005	6,925,394
A813/1678	Crystal Structure	National Phase	Application	Europe	01306060.3	13/07/2001	22/11/2006	1172374
A813/1678	Crystal Structure	National Phase	Continuation in Part	United States	09/953,607	17/09/2001	20/10/2009 14:36	7,606,670
A813/1708	Activation Induced Deaminase (AID)	National Phase	Application	Europe	03722838.4	09/05/2003	17/04/2013	1506288
A813/1708	Activation Induced Deaminase (AID)	National Phase	Continuation	United States	10/985,321	10/11/2004	26/10/2010	7,820,442
A813/1708	Activation Induced Deaminase (AID)	National Phase	Divisional	United States	12/911,292	09/05/2003	16/10/2012	8288160
A813/1708	Activation Induced Deaminase (AID)	National Phase	Application	United Kingdom	0217519.8	29/07/2002		
A813/1708	Activation Induced Deaminase (AID)	National Phase	Divisional	United States	13/606,696	07/09/2012		
A813/1708	Activation Induced Deaminase (AID)	National Phase	Application	United Kingdom	0213751.1	14/06/2002		
A813/1791	CST Emulsions	National Phase	Continuation in Part	United States	12/690,577	20/01/2010 10.44	13/03/2012	8,133,673
A813/1791	CST Emulsions	National Phase	Application	Europe	04798378.8	02/11/2004	02/04/2008	1680516
A813/1791	CST Emulsions	National Phase	Application	United States	11/417,449	03/05/2006	06/04/2010	7,691,576

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
A813/1798	GnRH conjugates	National Phase	Application	United States	10/552110	05/04/2004	20/04/2010	7,700,559
A813/1798	GnRH conjugates	National Phase	Application	Japan	2006-506091	05/04/2004	21/09/2010	4614943
A813/1798	GnRH conjugates	National Phase	Application	Europe	04725716.7	05/04/2004	15/10/2008	1613357
A813/1803	Compartmentalised Combinatorial Chemist	National Phase	Application	Canada	2520630	31/03/2004	09/11/2015	2520630
A813/1803	Compartmentalised Combinatorial Chemist	National Phase	Application	Australia	2004226693	31/03/2004	22/03/2012	2004/226693
A813/1803	Compartmentalised Combinatorial Chemist	National Phase	Application	United States	11/238,257	29/09/2005	16/05/2010 10:02	7,718,578
A813/1803	Compartmentalised Combinatorial Chemistry	National Phase	Application	Japan	2014-144285	31/03/2004	22/03/2017	6100736
A813/1803	Compartmentalised Combinatorial Chemistry	National Phase	Application	Europe	12172466.0	31/03/2004		
A813/1803	Compartmentalised Combinatorial Chemist	National Phase	Application	Europe	04724636.8	31/03/2004 09/28		
A813/1804	Selection By Compartmentalised Screening	National Phase	Application	Europe	04724631.9	31/03/2004	05/09/2012	EP1608976
A813/1804	Selection By Compartmentalised Screening	National Phase	Application	Canada	2,520,548	31/03/2004	19/01/2016	2520548
A813/1804	Selection By Compartmentalised Screening	National Phase	Application	Australia	2004225691	31/03/2004	07/10/2010	2004-225691
A813/1804	Selection By Compartmentalised Screening	National Phase	Divisional	Australia	2010224352	31/03/2004	22/12/2011	2010-224352
A813/1804	Selection By Compartmentalised Screening	National Phase	Divisional	Europe	11167399.8	31/03/2004		
A813/1804	Selection By Compartmentalised Screening	National Phase	Application	Japan	2014-246570	31/03/2004		
A813/1804	Selection By Compartmentalised Screening	National Phase	Application	United States	15/331,445	21/10/2016		
A813/1804	Selection By Compartmentalised Screening	National Phase	Continuation	United States	15/855,612	27/12/2017		
A813/1804	Selection By Compartmentalised Screening	National Phase	Continuation	United States	11/238,258	29/09/2005	20/09/2016	9448172

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
A813/1804	Selection By Compartmentalised Screening	National Phase	Continuation	United States	13/208,614	12/08/2011		
A813/1810	M4 Emulsions	National Phase	Divisional	Australia	2010200031	03/11/2004	25/06/2013	2010200031
A813/1810	M4 Emulsions	National Phase	Divisional	Europe	09010518.0	03/11/2004	17/08/2015	2145856
A813/1810	M4 Emulsions	National Phase	Application	Canada	2,544,841	11/03/2004	25/03/2014	2,544,841
A813/1810	M4 Emulsions	National Phase	Application	Australia	2004000288017	11/03/2004	08/10/2009	2004288017
A813/1810	M4 Emulsions	National Phase	Continuation	United States	13/527,342	19/06/2012	04/08/2015	9,086,835
A813/1810	M4 Emulsions	National Phase	Divisional	United States	12/538,392	10/08/2009 15:06		
A813/1857	Method For Generating Diversity 2	National Phase	Application	Europe	02735612.0	11/06/2002	28/08/2013	1399016
A813/1857	Method For Generating Diversity 2	National Phase	Application	Canada	2,449,264	11/06/2002	29/05/2012	2,449,264
A813/1857	Method For Generating Diversity 2	National Phase	Application	United States	10/733,532	11/06/2002	06/05/2008	7,368,259
A813/1857	Method For Generating Diversity 2	National Phase	Application	Japan	2003-503750	11/06/2002	04/12/2009 15:20	4418668
A813/1857	Method For Generating Diversity 2	National Phase	Application	Australia	2002310621	11/06/2002	17/01/2008	2002310621
A813/1897	Compartmentalised Screening	National Phase	Application	Japan	2007-536255	12/10/2005	22/09/2011	4829240
A813/1897	Compartmentalised Screening	National Phase	Divisional	Europe	12195355.8	12/10/2005	27/04/2016	2602018
A813/1897	Compartmentalised Screening	National Phase	Application	Europe	05792856.6	12/10/2005	14/12/2016	1842067
A813/1897	Compartmentalised Screening	National Phase	Application	Canada	2,582,465	12/10/2005	16/09/2014	2582465
A813/1897	Compartmentalised Screening	National Phase	Application	United States	11/665,145	12/10/2005	22/11/2016	9498759
A813/1897	Compartmentalised Screening	National Phase	Divisional	Europe	16194377.4	12/10/2005		
A813/1900	Directed Evolution of Nucleic Acids	National Phase	Divisional	Europe	10179380.0	10/10/2005	15/04/2015	EP2267163
A813/1900	Directed Evolution of Nucleic Acids	National Phase	Application	Europe	05792245.2	10/10/2005	05/10/2011	EP 1805324
A813/1900	Directed Evolution of Nucleic Acids	National Phase	Divisional	Europe	10179420.4	10/10/2005	04/03/2015	EP2270236
A813/1900	Directed Evolution of Nucleic Acids	National Phase	Divisional	Europe	10179400.6	10/10/2005	01/10/2014	EP2270235
A813/1900	Directed Evolution of Nucleic Acids	National Phase	Application	Japan	2013-077141	02/04/2013	18/03/2016	5903067
A813/1900	Directed Evolution of Nucleic Acids	National Phase	Divisional	Europe	15163413.6	10/10/2005		
A813/1900	Directed Evolution of Nucleic Acids	National Phase	Continuation	United States	15/012,209	10/10/2005		

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
A813/1900	Directed Evolution of Nucleic Acids	National Phase	Continuation	United States	15/588,210	10/10/2005		
A813/1900	Directed Evolution of Nucleic Acids	National Phase	Application	Canada	2,582,476	10/10/2005		
A813/1900	Directed Evolution of Nucleic Acids	National Phase	Continuation	United States	13/692,615	10/10/2005	17/11/2015	9,186,643
A813/1900	Directed Evolution of Nucleic Acids	National Phase	Application	United States	10/961,895	08/10/2004	28/06/2011	7968287
A813/1900	Directed Evolution of Nucleic Acids	National Phase		United States	US20160012209	01/02/2016		
A813/1900	Directed Evolution of Nucleic Acids	National Phase	Application	Japan	2015-235625	02/04/2013		
A813/1900	Directed Evolution of Nucleic Acids	National Phase	Application	United States	11/865,030	10/10/2005	12/05/2015	9,023,083
A813/1901	Compartmentalised Combinatorial Chemistry	National Phase	Application	Canada	2,582,470	12/10/2005	20/08/2013	2582470
A813/1901	Compartmentalised Combinatorial Chemistry	National Phase	Application	Japan	2007-536257	12/10/2005	04/04/2014	5509412
A813/1901	Compartmentalised Combinatorial Chemistry	National Phase	Divisional	Europe	12173230.9	12/10/2005		
A813/1901	Compartmentalised Combinatorial Chemistry	National Phase	Application	United States	11/238, 257	29/09/2005	18/06/2015	7718578
A813/1901	Compartmentalised Combinatorial Chemistry	National Phase	Application	Europe	05792864.0	12/10/2005		
A813/1935	Fluorescence Readout Device	National Phase	Application	United States	11/727,935	29/03/2007	17/08/2010	7,776,596
A813/1964	Novel synthetic route for caged GABA	National Phase	Application	United States	11/507,961	22/08/2006	15/06/2010	7,737,169
A813/1969	E10 Polymerase	National Phase	Application	Europe	07804064.9	24/08/2007	13/03/2013	EP2074211
A813/1969	E10 Polymerase	National Phase	Application	United States	12/440,374	24/08/2007	07/05/2013	8435775
A813/1969	E10 Polymerase	National Phase	Application	United Kingdom	0617365.1	06/09/2006		
A813/1985	Zinc Fingers	National Phase	Application	Europe	06820567.3	19/12/2006	20/03/2013	EP1974034
A813/1985	Zinc Fingers	National Phase	Application	United States	12/143,886	23/06/2008 09:57	22/09/2015	9,139,628
A813/1985	Zinc Fingers	National Phase	Divisional	United States	14/859,596	21/09/2015		
A813/1985	Zinc Fingers	National Phase	Application	Japan	2008-546588	19/12/2006		
A813/1985	Zinc Fingers	National Phase	Application	Australia	20060328193	19/12/2006	21/02/2013	2006328193
A813/2002	HU1 Polymerase	National Phase	Continuation	United States	13/789,655	23/10/2007	05/01/2016	9228179

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
A813/2002	HU1 Polymerase	National Phase	Application	Europe	07824279.9	23/10/2007	12/04/2017	EP2076592
A813/2002	HU1 Polymerase	National Phase	Application	United Kingdom	0623977.6	30/11/2006		
A813/2007	MitoSNO: a potential therapeutic for IR Injury (MitoSNO)	National Phase	Application	Australia	2007-300782	26/09/2007	12/12/2013	2007300782
A813/2007	MitoSNO: a potential therapeutic for IR Injury (MitoSNO)	National Phase	Application	New Zealand	575904	26/09/2007	05/03/2012	575904
A813/2007	MitoSNO: a potential therapeutic for IR Injury (MitoSNO)	National Phase	Application	Europe	07834884.4	26/09/2007	08/08/2012	EP2066680
A813/2007	MitoSNO: a potential therapeutic for IR Injury (MitoSNO)	National Phase	Application	Canada	2664744	26/09/2007	17/02/2015	2,664,744
A813/2007	MitoSNO: a potential therapeutic for IR Injury (MitoSNO)	National Phase	Continuation In Part	United States	12732,909	26/09/2007	02/06/2015	9,045,505
A813/2007	MitoSNO: a potential therapeutic for IR Injury (MitoSNO)	National Phase	Divisional	United States	14716,588	19/05/2015	25/04/2017	9,629,859
A813/2010	Deubiquitylating enzyme - trabid	National Phase	Application	Europe	07732861.5	21/05/2007	29/08/2012	EP2021471
A813/2010	Deubiquitylating enzyme - trabid	National Phase	Application	United States	12302,317	21/05/2007 13:23	07/07/2015	9,074,202
A813/2012	Mineral Precipitation Technique	National Phase	Application	Israel	2009/0199901	06/02/2008	01/03/2015	IL 199901
A813/2012	Mineral Precipitation Technique	National Phase	Application	India	2713/KOLNP/2009	06/02/2008 14:49	22/04/2016	272737
A813/2012	Mineral Precipitation Technique	National Phase	Application	Eurasia	2009/70716	06/02/2008 14:37	30/05/2014	019635
A813/2012	Mineral Precipitation Technique	National Phase	Application	United Kingdom	0802214.7	06/02/2008	16/12/2009 13:46	2451713
A813/2012	Mineral Precipitation Technique	National Phase	Application	South Africa	2009/05083	06/02/2008 14:30	28/04/2010	2009/05083
A813/2012	Mineral Precipitation Technique	National Phase	Application	Europe	08709331.6	06/02/2008 13:29	17/06/2015	EP2125847
A813/2012	Mineral Precipitation Technique	National Phase	Application	Singapore	200904684-4	06/02/2008 14:35	30/07/2010	154173
A813/2012	Mineral Precipitation Technique	National Phase	Application	Hong Kong	10105191.4	06/02/2008	11/12/2015	HK1138598
A813/2012	Mineral Precipitation Technique	National Phase	Application	Mexico	MX/A/2009/008281	06/02/2008 13:04	05/07/2011	288069

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
A813/2012	Mineral Precipitation Technique	National Phase	Application	China	20080004288.2	06/02/2008 11:24	10/09/2014	ZL20080004288.2
A813/2012	Mineral Precipitation Technique	National Phase	Application	Canada	2,676,146	06/02/2008 14:05	09/08/2016	2676146
A813/2012	Mineral Precipitation Technique	National Phase	Application	Australia	2008/212653	06/02/2008 15:30	06/09/2012	2008/212653
A813/2012	Mineral Precipitation Technique	National Phase	Application	South Korea	10-2009-7016904	06/02/2008 13:26	16/04/2015	10-1514470
A813/2012	Mineral Precipitation Technique	National Phase	Application	Japan	2009-548736	06/02/2008 11:31	05/06/2015	5756598
A813/2012	Mineral Precipitation Technique	National Phase	Application	Brazil	PI0807212-4	06/02/2008		
A813/2012	Mineral Precipitation Technique	National Phase	Application	United States	12/026,881	06/02/2008	15/11/2011	8,058,462
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Mexico	MX/a/2009/011234	17/04/2008	14/11/2011	292146
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Canada	2,684,492	17/04/2008	24/11/2015	2,684,492
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	New Zealand	NZ20080581178	17/04/2008 15:41	07/05/2012	581178
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Indonesia	W-00200803228	17/04/2008	29/06/2016	IDP000041982
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Honduras	2009-003038	17/04/2008	02/03/2012	5187
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	South Africa	2009/07726	17/04/2008 14:57	26/01/2011	2009/07726
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Nicaragua	2009000169	17/04/2008	09/11/2015	2415RFP1
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Japan	2010-503589	17/04/2008	20/09/2013	5366930
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Israel	201552	17/04/2008	01/12/2015	201552
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Malaysia	PI020094369	17/04/2008 15:16	30/04/2013	MY-148451-A
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	United States	12696,053	17/04/2008 11:17	26/06/2012	8,206,717
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Eurasia	200901421	17/04/2008	30/05/2013	018073
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Singapore	200906894-1	17/04/2008	31/05/2012	156295
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	South Korea	1020097023939	17/04/2008	17/03/2016	10-1605881

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Australia	2008240436	17/04/2008 11:15	30/06/2011	2008240436
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	China	200880020620.4	17/04/2008 11:19	16/10/2013	ZL20088002060.4
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Europe	08737025.0	17/04/2008 11:50	24/08/2016	EP2144934
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Colombia	09-123670	17/04/2008 11:04	01/04/2013	2667
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Costa Rica	11079	17/04/2008	18/12/2015	3243
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Nigeria	NGC/2009547	17/04/2008	15/09/2010	NG/C/2009/547
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	India	7128/DELNP/2009	17/04/2008	01/01/2015	264519
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Vietnam	1-2009-02458	17/04/2008 15:16	07/02/2014	12363
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Philippines	1-2009-501995	17/04/2008	03/10/2014	12009501995
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Brazil	PI0810418.2	17/04/2008 16:20		
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Egypt	FCI/NA/1529/2009	17/04/2008		
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Sri Lanka	15573	10/03/2010		
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Guatemala	A-2009-00271	17/04/2008 11:22		
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	El Salvador	E-3395-2009 P8679-2009	17/04/2008		
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Brunei	RER120140023	07/04/2009	29/04/2014	MY-149451-A
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Ecuador	SP-09-9726	10/11/2009		
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Ukraine	2009 11796	17/04/2008	25/12/2012	100377
A813/2098	Determining dead regions of nerve fibres	National Phase	Application	United States	12/172,821	14/07/2008	04/11/2014	8,880,180
A813/2179	Pip2 peptide	National Phase	Application	United States	12/996,307	15/05/2009	05/11/2013	8575305
A813/2179	Pip2 peptide	National Phase	Application	Europe	09757740.7	15/05/2009		
A813/2213	Phosphate Binder	National Phase	Application	Japan	2011/521635	05/08/2009	11/09/2015	5805532

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
A813/2213	Phosphate Binder	National Phase	Application	South Korea	10-2011-7004981	05/08/2009	26/08/2016	10-1653423
A813/2213	Phosphate Binder	National Phase	Application	Australia	2009278906	05/08/2009	26/02/2015	2009278906
A813/2213	Phosphate Binder	National Phase	Application	United Kingdom	0913684.7	05/08/2009 15:05	22/12/2010	2462374
A813/2213	Phosphate Binder	National Phase	Application	Hong Kong	11107682.9	05/08/2009	04/08/2017	HK 1153-02
A813/2213	Phosphate Binder	National Phase	Application	Mexico	MX/A/2011/001258	05/08/2009	13/01/2012	294631
A813/2213	Phosphate Binder	National Phase	Application	Eurasia	201170116	05/08/2009	31/08/2015	021705
A813/2213	Phosphate Binder	National Phase	Application	Singapore	201100555-0	05/08/2009	30/11/2011	198355
A813/2213	Phosphate Binder	National Phase	Application	Israel	210913	05/08/2009	01/11/2014	210913
A813/2213	Phosphate Binder	National Phase	Application	Europe	09784878.2	05/08/2009	13/07/2016	EP2320884
A813/2213	Phosphate Binder	National Phase	Application	China	200980134870.5	05/08/2009	13/05/2015	ZL200980134870.5
A813/2213	Phosphate Binder	National Phase	Application	South Africa	2011/00821	05/08/2009	28/09/2011	2011/00821
A813/2213	Phosphate Binder	National Phase	Application	Canada	2732226	05/08/2009	12/09/2017	CA 2732226
A813/2213	Phosphate Binder	National Phase	Application	United States	12/536.014	05/08/2009 15:42	17/05/2011	7,943,864
A813/2213	Phosphate Binder	National Phase	Application	India	545/KOLNP/2011	05/08/2009		
A813/2213	Phosphate Binder	National Phase	Application	Brazil	P10917503-2	05/08/2009		
A813/2222	humanised anti-IL-25 antibody	National Phase	Application	South Korea	10-2011-7009937	30/09/2009	19/09/2016	101659452
A813/2222	humanised anti-IL-25 antibody	National Phase	Application	Hong Kong	11103260.3	30/09/2009	02/10/2015	HK1154-022
A813/2222	humanised anti-IL-25 antibody	National Phase	Application	Mexico	MX/a/2011/003351	30/09/2009	03/04/2014	319011
A813/2222	humanised anti-IL-25 antibody	National Phase	Application	Singapore	201102198-7	30/09/2009	16/10/2013	169849
A813/2222	humanised anti-IL-25 antibody	National Phase	Application	China	200980147932.6	30/09/2009	22/10/2014	ZL200980147932.6
A813/2222	humanised anti-IL-25 antibody	National Phase	Application	Europe	09795802.9	30/09/2009	25/02/2015	2344536
A813/2222	humanised anti-IL-25 antibody	National Phase	Application	Japan	2011-528454	30/09/2009	27/03/2015	5719771
A813/2222	humanised anti-IL-25 antibody	National Phase	Application	United States	13/121.896	30/09/2009	25/02/2014	9,658,169
A813/2222	humanised anti-IL-25 antibody	National Phase	Application	Monteregro	P-2015-78	18/06/2015		

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
A813/2222	humanised anti-IL-25 antibody	National Phase	Application	Canada	2,739,050	30/09/2009		
A813/2222	humanised anti-IL-25 antibody	National Phase	Application	Brazil	PI-09190627	30/09/2009		
A813/2222	humanised anti-IL-25 antibody	National Phase	Application	India	2671/DELNP/2001	30/09/2009		
A813/2222	humanised anti-IL-25 antibody	National Phase	Application	New Zealand	592274	30/09/2009	11/12/2012	592274
A813/2222	humanised anti-IL25 antibody	National Phase	Application	Australia	2009299465	30/09/2009		
A813/2234	Fluorocarbon emulsion stabilizing surfac	National Phase	Application	Europe	2007836615	07/08/2007		
A813/2234	Fluorocarbon emulsion stabilizing surfac	National Phase	Application	United States	12/310,048	07/08/2007	21/04/2015	9,012,390
A813/2241	LRRK2 substrate	National Phase	Continuation In Part	United States	12/553,932	03/09/2009	26/06/2012	8,206,942
A813/2241	LRRK2 substrate	National Phase	Continuation In Part	United States	12/244,715	02/10/2008	24/05/2011	7,947,468
A813/2261	anti-IL-25 receptor antibodies	National Phase	Application	Japan	2012-504066	31/03/2010	26/06/2015	5767625
A813/2261	anti-IL-25 receptor antibodies	National Phase	Divisional	United States	14/056559	15/10/2013	07/10/2014	8852589
A813/2261	anti-IL-25 receptor antibodies	National Phase	Application	United States	13/262123	31/03/2010	19/11/2013	8566037
A813/2261	anti-IL-25 receptor antibodies	National Phase	Application	China	201080022541.4	31/03/2010	10/06/2015	ZL201080022541.4
A813/2261	anti-IL-25 receptor antibodies	National Phase	Application	Australia	2010233535	31/03/2010	12/06/2014	2010233535
A813/2261	anti-IL-25 receptor antibodies	National Phase	Application	Europe	10712110.5	31/03/2010	24/05/2017	2417161
A813/2261	anti-IL-25 receptor antibodies	National Phase	Application	Hong Kong	12111452.4	31/03/2010	30/10/2015	HK1170745
A813/2261	anti-IL-25 receptor antibodies	National Phase	Application	India	8006/DELNP/2011	31/03/2010		
A813/2261	anti-IL-25 receptor antibodies	National Phase	Application	Canada	2757104	31/03/2010		
A813/2265	Gadolinium-tagged liposome contrast agent	National Phase	Application	Japan	2012-539414	19/11/2010	12/02/2016	5883797
A813/2265	Gadolinium-tagged liposome contrast agent	National Phase	Application	China	201080061977.4	19/11/2010	18/06/2014	201080061977.4
A813/2265	Gadolinium-tagged liposome contrast agent	National Phase	Application	Hong Kong	12111348.2	19/11/2010	18/12/2015	1170437

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
A813/2265	Gadolinium-tagged liposome contrast agent	National Phase	Application	Europe	10781995.5	19/11/2010	18/03/2015	2501415
A813/2265	Gadolinium-tagged liposome contrast agent	National Phase	Continuation	United States	15463,964	19/11/2010		
A813/2265	Gadolinium-tagged liposome contrast agent	National Phase	Divisional	Japan	2015-79529	19/11/2010		
A813/2278	Neural Excitation	National Phase	Application	Europe	08789109.9	21/09/2008		
A813/2278	Neural Excitation	National Phase	Application	United States	12/172,850	14/07/2008	05/03/2013	8,391,993
A813/2291	Predictive use of CpG methylation	National Phase	Application	Europe	10702168.5	29/01/2010	13/04/2015	2391730
A813/2296	AID Mutants	National Phase	Application	Russia	2011144569	05/04/2010	27/12/2014	2537264
A813/2296	AID Mutants	National Phase	Application	Europe	10723293.6	05/04/2010	02/07/2014	2414507
A813/2296	AID Mutants	National Phase	Application	China	201080023311.X	05/04/2010	06/01/2016	ZL 201080023311.X
A813/2296	AID Mutants	National Phase	Application	Japan	502830/2012	05/04/2010	23/01/2015	5683566
A813/2296	AID Mutants	National Phase	Application	Australia	2010230985	05/04/2010	07/01/2016	2010230985
A813/2296	AID Mutants	National Phase	Application	United States	13262,187	05/04/2010	20/06/2017	9683226
A813/2296	AID Mutants	National Phase	Application	India	7514/DELNP/2011	05/04/2010		
A813/2296	AID Mutants	National Phase	Application	Canada	2,757,178	05/04/2010		
A813/2305	Incorporation of alkene functional group	National Phase	Application	United States	13/376,068	02/12/2011	16/01/2018	9666956
A813/2305	Incorporation of alkene functional group	National Phase	Application	Europe	10727116.5	02/06/2010		
A813/2404	Oesophageal prognostic signature	National Phase	Application	Europe	11718762.5	24/03/2011	28/09/2016	2550534
A813/2404	Oesophageal prognostic signature	National Phase	Continuation	United States	15/288934	07/10/2016		
A813/2404	Oesophageal prognostic signature	National Phase	Application	United States	13/636,958	24/09/2012	28/03/2017	9,608,122
A813/2453	Calcium phosphate delivery	National Phase	Application	Singapore	11201603261P	05/11/2014		
A813/2453	Calcium phosphate delivery	National Phase	Application	Hong Kong	17102208.5	05/11/2014		
A813/2453	Calcium phosphate delivery	National Phase	Application	Mexico	MX/A/2016/005415	05/11/2014		
A813/2453	Calcium phosphate delivery	National Phase	Application	South Africa	2016/02906	05/11/2014		
A813/2453	Calcium phosphate delivery	National Phase	Application	Australia	2014345334	05/11/2014		

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
A813/2453	Calcium phosphate delivery	National Phase	Application	Eurasia	201690659	05/11/2014		
A813/2453	Calcium phosphate delivery	National Phase	Application	Japan	2016-551077	05/11/2014		
A813/2453	Calcium phosphate delivery	National Phase	Application	China	201480060734.7	05/11/2014		
A813/2453	Calcium phosphate delivery	National Phase	Application	India	201637015330	05/11/2014		
A813/2453	Calcium phosphate delivery	National Phase	Application	Europe	14799845.4	05/11/2014		
A813/2453	Calcium phosphate delivery	National Phase	Application	Brazil	BR1120160098099	05/11/2014		
A813/2453	Calcium phosphate delivery	National Phase	Application	Canada	2929123	05/11/2014		
A813/2453	Calcium phosphate delivery	National Phase	Application	United States	15/033750	05/11/2014		
A813/2453	Calcium phosphate delivery	National Phase	Application	South Korea	10-2016-7014309	05/11/2014		
A813/2453	Calcium phosphate delivery	National Phase	Application	Israel	245380	05/11/2014		
A813/2476	Improved cytosponge	National Phase	Application	Japan	JF2012-536396	11/11/2010	05/08/2015	JP5759473
A813/2476	Improved cytosponge	National Phase	Application	Europe	10795447.0	11/11/2010	29/03/2017	EP2498684
A813/2476	Improved cytosponge	National Phase	Application	Australia	2010317794	11/11/2010	15/01/2015	2010317794
A813/2476	Improved cytosponge	National Phase	Application	China	201060061260.X	11/11/2010	25/03/2015	CN102711628
A813/2476	Improved cytosponge	National Phase	Application	Canada	CA20102780621	11/11/2010		
A813/2476	Improved cytosponge	National Phase	Application	Hong Kong	13103252.2	15/03/2013		
A813/2476	Improved cytosponge	National Phase	Application	United States	13/509,035	10/05/2012		
A813/2476	Improved cytosponge	National Phase	Application	India	4165/DELNP/2012	11/11/2010		
A813/2479	TFF3 Barnett's biomarker	National Phase	Application	United States	12/833,546	09/07/2010 11:29	29/04/2014	8706736
A813/2499	genetic encoding of ubiquitination	National Phase	Application	Europe	11715594.5	23/03/2011		
A813/2523	Artificial nucleic acid system	National Phase	Application	Japan	2013-506725	14/04/2011	02/09/2016	5997691
A813/2523	Artificial nucleic acid system	National Phase	Application	United States	13/695,377	14/04/2011	27/10/2015	9,169,471
A813/2523	Artificial nucleic acid system	National Phase	Divisional	United States	14/872,814	14/04/2011		
A813/2523	Artificial nucleic acid system	National Phase	Application	Canada	2,797,749	14/04/2011		
A813/2523	Artificial nucleic acid system	National Phase	Divisional	Japan	2016-099312	14/04/2011		

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
A813/2523	artificial nucleic acid system	National Phase	Application	United Kingdom	1007384.9	30/04/2010 10:42		
A813/2523	Artificial nucleic acid system	National Phase	Application	Europe	11731447.6	14/04/2011		
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	South Korea	2012-7027973	30/03/2011		
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	Ecuador	EC2012SP12202	01/10/2012		
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	Europe	11763357.8	30/03/2011		
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	Singapore	20120070249	30/03/2011		
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	Japan	2013-0502790	30/03/2011		
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	New Zealand	2011-0602720	30/03/2011		
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	Hong Kong	20130112430	05/11/2013		
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	Ukraine	20120012360	30/03/2011		
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	Chile	20120002745	30/03/2011		
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	China	201180016673.0	30/03/2011		
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	Mexico	2012-0011479	30/03/2011		AU2011233232
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	Australia	2011-235232	30/03/2011	21/05/2015	
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	Costa Rica	20120553	30/10/2012		
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	Eurasia	20120090977	30/03/2011		
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	Peru	20120001630	30/03/2011		
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	Brazil	112012024786	30/03/2011		
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	Canada	2011-2795043	30/09/2011		6143676
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	Japan	2013-550942	25/01/2012	19/05/2017	ZL201280014266.0
A813/2566	Mineral oxide Oxygen sensors	National Phase	Application	China	201280014266.0	25/01/2012	27/04/2016	0
A813/2566	Mineral oxide Oxygen sensors	National Phase	Application	United States	13/991.433	25/01/2012	29/12/2015	9.222.925
A813/2566	Mineral oxide Oxygen sensors	National Phase	Application	Brazil	BR1120130189866	25/01/2012		
A813/2566	Mineral oxide Oxygen sensors	National Phase	Application	Europe	12708360.8	25/01/2012	07/03/2018	2668495
A813/2566	Mineral oxide Oxygen sensors	National Phase	Application	India	1470/MUMNP/2013	25/01/2012		

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
A813/2566	Mineral oxide Oxygen sensors	National Phase	Application	Israel	IL20130227621	25/01/2012		
A813/2566	Mineral oxide Oxygen sensors	National Phase	Application	Russia	2013136610	25/01/2012		
A813/2572	Arabino-DNA polymerases	National Phase	Application	Europe	13723189.0	19/04/2013		
A813/2572	Arabino-DNA polymerases	National Phase	Application	United States	147395.429	19/04/2014	12/03/2018	9,914,914
A813/2661	Guanabenz analogues against GADD34	National Phase	Application	Europe	14700810.7	10/01/2014	13/07/2016	2943467
A813/2661	Guanabenz analogues against GADD34	National Phase	Application	Australia	2014204831	10/01/2014		
A813/2661	Guanabenz analogues against GADD34	National Phase	Application	United States	14760,350	10/01/2014	02/11/2016	14,760,350
A813/2661	Guanabenz analogues against GADD34	National Phase	Application	Canada	2,896,976	10/01/2014		
A813/2661	Guanabenz analogues against GADD34	National Phase	Divisional	Europe	16172383.8	10/01/2014		
A813/2661	Guanabenz analogues against GADD34	National Phase	Application	Brazil	BR 11 2015 016433 1	10/01/2014		
A813/2661	Guanabenz analogues against GADD34	National Phase	Application	Russia	RU2015 127827	10/01/2014		
A813/2661	Guanabenz analogues against GADD34	National Phase	Application	India	5769/DELNP/2015	10/01/2014		
A813/2661	Guanabenz analogues against GADD34	National Phase	Application	Mexico	MX/a/2015/008977	10/01/2014		
A813/2661	Clearing misfolded proteins (GADD34)	National Phase	Application	United Kingdom	1300435.3	10/01/2013		
A813/2661	Guanabenz analogues against GADD34	National Phase	Application	South Korea	10-2015-7019864	10/01/2014		
A813/2661	Guanabenz analogues against GADD34	National Phase	Application	China	201480004604.1	10/01/2014		
A813/2661	Guanabenz analogues against GADD34	National Phase	Application	Israel	239629	10/01/2014		
A813/2661	Guanabenz analogues against GADD34	National Phase	Application	Japan	JP2015-552030	10/01/2014		
A813/2670	pip6 series of cell penetrating peptides	National Phase	Application	Australia	2012300633	29/08/2012	10/08/2017	2012300633

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
A813/2670	pip6 series of cell penetrating peptides	National Phase	Application	Japan	2014-527734	29/09/2012	20/01/2017	6077543
A813/2670	pip6 series of cell penetrating peptides	National Phase	Application	United States	14/240,832	25/02/2014	05/04/2016	9302014
A813/2670	pip6 series of cell penetrating peptides	National Phase	Application	Europe	12756546.3	29/08/2012		
A813/2670	pip6 series of cell penetrating peptides	National Phase	Application	Brazil	BR/11201400490 25	29/08/2012		
A813/2670	pip6 series of cell penetrating peptides	National Phase	Application	Hong Kong	14107703.7	29/08/2012		
A813/2670	pip6 series of cell penetrating peptides	National Phase	Application	India	357/MUMNP/2014	29/08/2012		
A813/2670	pip6 series of cell penetrating peptides	National Phase	Application	China	201280042626.7	29/08/2012		
A813/2670	pip6 series of cell penetrating peptides	National Phase	Application	Canada	2846216	29/08/2012		
A813/2707	Cytosponge for use in detecting H. pylori infection	National Phase	Application	Europe	12809298.8	22/11/2012		
A813/2733	Stabilised silicate compositions as anti-perspirants	National Phase	Application	United States	15/117784	13/02/2015		
A813/2733	Stabilised silicate compositions as anti-perspirants	National Phase	Application	South Korea	10-2016-7021929	13/02/2015		
A813/2733	Stabilised silicate compositions as anti-perspirants	National Phase	Application	India	201627027037	13/02/2015		
A813/2733	Stabilised silicate compositions as anti-perspirants	National Phase	Application	Mexico	MX/A/2016/010263	13/02/2015		
A813/2733	Stabilised silicate compositions as anti-perspirants	National Phase	Application	Canada	2939050	13/02/2015		
A813/2733	Stabilised silicate compositions as anti-perspirants	National Phase	Application	Eurasia	201691363	13/02/2015		
A813/2733	Stabilised silicate compositions as anti-perspirants	National Phase	Application	China	201580008559.1	13/02/2015		
A813/2733	Stabilised silicate compositions as anti-perspirants	National Phase	Application	Australia	2015216712	13/02/2015		
A813/2733	Stabilised silicate compositions as anti-perspirants	National Phase	Application	Brazil	BR 11 2016 0186540	13/02/2015		
A813/2733	Stabilised silicate compositions as anti-perspirants	National Phase	Application	South Africa	2016/05438	13/02/2015		

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
A813/2733	Stabilised silicate compositions as anti-perspirants	National Phase	Application	Hong Kong	17105959.9	13/02/2015		
A813/2733	Stabilised silicate compositions as anti-perspirants	National Phase	Application	New Zealand	729361	13/02/2015		
A813/2733	Stabilised silicate compositions as anti-perspirants	National Phase	Application	Japan	2016-551224	13/02/2015		
A813/2733	Stabilised silicate compositions as anti-perspirants	National Phase	Application	Europe	15707170.5	13/02/2015		
A813/2737	Point-of-care TB diagnostic test	National Phase	Application	United States	15/022.041	15/03/2016		
A813/2737	Point-of-care TB diagnostic test	National Phase	Application	Brazil	BR 11 2016 005745 7	17/03/2016		
A813/2737	Point-of-care TB diagnostic test	National Phase	Application	Europe	14781260.6	15/04/2016		
A813/2737	Point-of-care TB diagnostic test	National Phase	Application	India	201647009255	17/03/2016		
A813/2737	Point-of-care TB diagnostic test	National Phase	Application	Japan	2016-542382	24/05/2016		
A813/2737	Point-of-care TB diagnostic test	National Phase	Application	South Africa	2016/01881	17/03/2016		
A813/2737	Point-of-care TB diagnostic test	National Phase	Application	Russia	2016114503	15/04/2016		
A813/2737	Point-of-care TB diagnostic test	National Phase	Application	China	201480062851.7	17/09/2014		
A813/2737	Point-of-care TB diagnostic test	National Phase	Application	Australia	2014322821	10/03/2016		
A813/2737	Point-of-care TB diagnostic test	National Phase	Application	Canada	2924405	17/03/2016		
A813/2741	Kis/Kid - Part2	National Phase	Application	Europe	12775131.1	17/09/2012		
A813/2741	Kis/Kid - Part2	National Phase	Application	United States	14/345.138	17/09/2012		
A813/2743	Ubiquitin chain sequencing method	National Phase	Application	United States	14/346.284	20/03/2014	07/03/2017	9587265
A813/2743	Ubiquitin chain sequencing method	National Phase	Application	Europe	12766385.4	24/09/2012		
A813/2749	Method for detecting and counting DNA or protein molecules	National Phase	Application	Europe	14718147.3	09/04/2014	14/10/2015	EP2828408
A813/2749	Method for detecting and counting DNA or protein molecules	National Phase	Application	Australia	2014252805	16/10/2014		
A813/2749	Method for detecting and counting DNA or protein molecules	National Phase	Application	Australia	2014252804	16/10/2014		

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
A813/2749	Method for detecting and counting DNA or protein molecules	National Phase	Application	Canada	2907868	09/04/2014		
A813/2749	Method for detecting and counting DNA or protein molecules	National Phase	Divisional	Europe	1419499.3	09/04/2014		
A813/2749	Method for detecting and counting DNA or protein molecules	National Phase	Application	United States	14782.654	06/10/2015		
A813/2749	Method for detecting and counting DNA or protein molecules	National Phase	Application	Brazil	BR 11 2015 025762 3	09/04/2014		
A813/2749	Method for detecting and counting DNA or protein molecules	National Phase	Application	China	201480020429	09/04/2014		
A813/2749	Method for detecting and counting DNA or protein molecules	National Phase	Application	China	201480020411.5	09/04/2014		
A813/2749	Method for detecting and counting DNA or protein molecules	National Phase	Application	Europe	14718148.1	07/12/2015	14/10/2015	2826409
A813/2749	Method for detecting and counting DNA or protein molecules	National Phase	Application	South Korea	10-2015-7032056	09/04/2014		
A813/2749	Method for detecting and counting DNA or protein molecules	National Phase	Application	United States	14782.650	06/10/2015		
A813/2749	Method for detecting and counting DNA or protein molecules	National Phase	Application	Brazil	BR 11 2015 025763 1	09/04/2014		
A813/2749	Method for detecting and counting DNA or protein molecules	National Phase	Application	Canada	2907865	09/04/2014		
A813/2753	Diagnostic biomarker signature for inconspicuous esophageal adenocarcinoma	National Phase	Application	China	201380038430.6	17/05/2013	21/11/2017	1045081475
A813/2753	Diagnostic biomarker signature for inconspicuous esophageal adenocarcinoma	National Phase	Application	Canada	2,873,627	17/05/2013		
A813/2753	Diagnostic biomarker signature for inconspicuous esophageal adenocarcinoma	National Phase	Application	Europe	13732214.5	17/05/2013		
A813/2753	Diagnostic biomarker signature for inconspicuous esophageal adenocarcinoma	National Phase	Application	United States	14/402,061	17/05/2013		

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
A813/2753	Diagnostic biomarker signature for inconspicuous esophageal adenocarcinoma	National Phase	Application	Hong Kong	15109500.7	17/05/2013		
A813/2755	Risk stratification for progression to EAC	National Phase	Application	China	201380038453.7	16/05/2013		
A813/2755	Risk stratification for progression to EAC	National Phase	Application	United States	14/401,725	16/05/2013		
A813/2755	Risk stratification for progression to EAC	National Phase	Application	Canada	2,873,800	16/05/2013		
A813/2755	Risk stratification for progression to EAC	National Phase	Application	Hong Kong	15109498.0	25/09/2015		
A813/2755	Risk stratification for progression to EAC	National Phase	Application	Europe	13732213.7	16/05/2013		
A813/2765	Norbormene Modified Peptides and their labelling ITH Tetrazine Compounds	National Phase	Application	Europe	13711926.9	21/01/2013	21/03/2018	2804872
A813/2765	Norbormene Modified Peptides and their labelling ITH Tetrazine Compounds	National Phase	Application	United States	14/373,292	21/02/2013		
A813/2765	Norbormene Modified Peptides and their labelling ITH Tetrazine Compounds	National Phase	Application	China	201380015571.6	21/01/2013		
A813/2771	LITA liposome nanoparticle formulation	National Phase	Application	Canada	20132882705	28/08/2013		
A813/2771	LITA liposome nanoparticle formulation	National Phase	Application	Hong Kong	15112861.4	28/08/2013		
A813/2771	LITA liposome nanoparticle formulation	National Phase	Application	Europe	13760080.5	28/08/2013		
A813/2771	LITA liposome nanoparticle formulation	National Phase	Application	Japan	2015-529120	28/08/2013		
A813/2771	LITA liposome nanoparticle formulation	National Phase	Application	China	201380055336.1	28/08/2013		
A813/2771	LITA liposome nanoparticle formulation	National Phase	Application	Australia	2013308245	28/08/2013		
A813/2771	LITA liposome nanoparticle formulation	National Phase	Application	United States	14/424,332	28/08/2013		
A813/2771	LITA liposome nanoparticle formulation	National Phase	Application	India	777KOLNP/2015	28/08/2013		
A813/2802	Rapid site-specific labelling of proteins, demonstrated by an alkyne cycloaddition	National Phase	Application	Europe	13734818.1	15/05/2013	06/09/2017	2852664

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
A813/2802	Rapid site-specific labelling of proteins, demonstrated by an alkyne cycloaddition	National Phase	Application	China	201380037290.0	15/05/2013		
A813/2802	Rapid site-specific labelling of proteins, demonstrated by an alkyne cycloaddition	National Phase	Application	Brazil	BR112014028588-8	15/05/2013		
A813/2802	Rapid site-specific labelling of proteins, demonstrated by an alkyne cycloaddition	National Phase	Application	India	9922/DELNP/2014	15/05/2013		
A813/2802	Rapid site-specific labelling of proteins, demonstrated by an alkyne cycloaddition	National Phase	Application	Japan	2015-512124	17/12/2014		
A813/2802	Rapid site-specific labelling of proteins, demonstrated by an alkyne cycloaddition	National Phase	Application	Canada	2,873,793	15/05/2013		
A813/2802	Rapid site-specific labelling of proteins, demonstrated by an alkyne cycloaddition	National Phase	Application	United States	14/401,803	17/11/2014		
A813/2802	Rapid site-specific labelling of proteins, demonstrated by an alkyne cycloaddition	National Phase	Application	Hong Kong	15109341.0	23/09/2015		
A813/2808	Diagnosis of high grade dysplasia	National Phase	Application	Europe	13/31426.6	17/05/2013	19/07/2017	2850209
A813/2808	Diagnosis of high grade dysplasia	National Phase	Application	United States	14/402,034	17/05/2013		
A813/2808	Diagnosis of high grade dysplasia	National Phase	Application	Hong Kong	15109503.4	25/09/2015		
A813/2812	Ang2 specific binder	National Phase	Application	Australia	2013366050	20/12/2013		
A813/2812	Ang2 specific binder	National Phase	Application	China	201350073337.9	20/12/2013		
A813/2812	Ang2 specific binder	National Phase	Application	Canada	2,895,645	20/12/2013		
A813/2812	Ang2 specific binder	National Phase	Application	Japan	2015-548770	20/12/2013		
A813/2812	Ang2 specific binder	National Phase	Application	Europe	13815108.9	20/12/2013		
A813/2812	Ang2 specific binder	National Phase	Application	United States	14/653,734	20/12/2013		
A813/2822	AP30 antibody structure (with S1 Andrews) & structure-based peptide design for vaccine (with CTD)	National Phase	Application	Australia	2015310671	04/09/2015		

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
A813/2822	AP33 antibody structure (with St Andrews) & structure-based peptide design for vaccine (with CTD)	National Phase	Application	Hong Kong	17107584.8	04/09/2015		
A813/2822	AP33 antibody structure (with St Andrews) & structure-based peptide design for vaccine (with CTD)	National Phase	Application	Japan	2017-510310	04/09/2015		
A813/2822	AP33 antibody structure (with St Andrews) & structure-based peptide design for vaccine (with CTD)	National Phase	Application	China	2015800476677	04/09/2015		
A813/2822	AP33 antibody structure (with St Andrews) & structure-based peptide design for vaccine (with CTD)	National Phase	Application	Russia	2017111044	04/09/2015		
A813/2822	AP33 antibody structure (with St Andrews) & structure-based peptide design for vaccine (with CTD)	National Phase	Application	Brazil	BR112017003138-6	04/09/2015		
A813/2822	AP33 antibody structure (with St Andrews) & structure-based peptide design for vaccine (with CTD)	National Phase	Application	India	201717007371	04/09/2015		
A813/2822	AP33 antibody structure (with St Andrews) & structure-based peptide design for vaccine (with CTD)	National Phase	Application	United States	15/607,676	04/09/2015		
A813/2822	AP33 antibody structure (with St Andrews) & structure-based peptide design for vaccine (with CTD)	National Phase	Application	Canada	2,958,030	04/09/2015		
A813/2822	AP33 antibody structure (with St Andrews) & structure-based peptide design for vaccine (with CTD)	National Phase	Application	Europe	15762666.2	04/09/2015		
A813/2855	Stabilised silicate compositions	National Phase	Application	China	201560018382.3	13/02/2015		
A813/2855	Stabilised silicate compositions	National Phase	Application	United States	15/119071	13/02/2015		
A813/2855	Stabilised silicate compositions	National Phase	Application	Japan	2016-551833	13/02/2015		
A813/2855	Stabilised silicate compositions	National Phase	Application	Singapore	11201606656Q	13/02/2015		
A813/2855	Stabilised silicate compositions	National Phase	Application	Hong Kong	16114700.4	13/02/2015		
A813/2855	Stabilised silicate compositions	National Phase	Application	India	201627027697	13/02/2015		
A813/2855	Stabilised silicate compositions	National Phase	Application	South Korea	10-2016-7024827	13/02/2015		

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
A813/2855	Stabilised silicate compositions	National Phase	Application	Australia	2015216711	13/02/2015		
A813/2855	Stabilised silicate compositions	National Phase	Application	Eurasia	201691441	13/02/2015		
A813/2855	Stabilised silicate compositions	National Phase	Application	New Zealand	723746	13/02/2015		
A813/2855	Stabilised silicate compositions	National Phase	Application	Canada	2939419	13/02/2015		
A813/2855	Stabilised silicate compositions	National Phase	Application	Europe	15707169.7	13/02/2015		
A813/2887	A gene expression panel (90 genes) to identify BE patients at risk for progressing to cancer	PCT	Application	United Kingdom	GB1513060.2	24/07/2015		
A813/2887	40 gene expression prognostic panel	PCT	Application	United States	15/747117	24/07/2016		
A813/2887	40 gene expression prognostic panel	PCT	Application	Europe	16738211.8	24/07/2016		
A813/2888	new risk stratification biomarker panel for progression from BE to EAC obtained from BEST2 patient s	National Phase	Application	Canada	2901150	19/02/2014		
A813/2888	new risk stratification biomarker panel for progression from BE to EAC obtained from BEST2 patient s	National Phase	Application	Australia	2014220484	19/02/2014		
A813/2888	new risk stratification biomarker panel for progression from BE to EAC obtained from BEST2 patient s	National Phase	Application	Hong Kong	16106771.4	13/06/2016		
A813/2888	new risk stratification biomarker panel for progression from BE to EAC obtained from BEST2 patient s	National Phase	Application	United States	14768,740	19/02/2014		
A813/2888	new risk stratification biomarker panel for progression from BE to EAC obtained from BEST2 patient s	National Phase	Application	India	8382/DELNP/2015	19/02/2014		
A813/2888	new risk stratification biomarker panel for progression from BE to EAC obtained from BEST2 patient s	National Phase	Application	Japan	2015-559546	19/04/2014		
A813/2888	new risk stratification biomarker panel for progression from BE to EAC obtained from BEST2 patient s	National Phase	Application	Europe	14706672.4	19/02/2014		
A813/2888	new risk stratification biomarker panel for progression from BE to EAC obtained from BEST2 patient s	National Phase	Application	China	201490010049.3	19/02/2014	31/10/2017	1052643795

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
A813/2898	Hydrogenation of graphene for 3D image reconstruction of proteins using cryo-EM	National Phase	Application	Singapore	11201600756U	07/08/2014		
A813/2898	Hydrogenation of graphene for 3D image reconstruction of proteins using cryo-EM	National Phase	Application	South Korea	10-2016-7003594	07/08/2014		
A813/2898	Hydrogenation of graphene for 3D image reconstruction of proteins using cryo-EM	National Phase	Application	Japan	2016-533949	07/08/2014		
A813/2898	Hydrogenation of graphene for 3D image reconstruction of proteins using cryo-EM	National Phase	Application	United States	14/911718	07/08/2014		
A813/2898	Hydrogenation of graphene for 3D image reconstruction of proteins using cryo-EM	National Phase	Application	South Africa	2016/00919	07/08/2014		
A813/2898	Hydrogenation of graphene for 3D image reconstruction of proteins using cryo-EM	National Phase	Application	Canada	2,919,271	07/08/2014		
A813/2898	Hydrogenation of graphene for 3D image reconstruction of proteins using cryo-EM	National Phase	Application	Hong Kong	16113114.6	15/11/2016		
A813/2898	Hydrogenation of graphene for 3D image reconstruction of proteins using cryo-EM	National Phase	Application	Australia	2014307798	07/08/2014		
A813/2898	Hydrogenation of graphene for 3D image reconstruction of proteins using cryo-EM	National Phase	Application	Europe	14750617.4	07/08/2014		
A813/2898	Hydrogenation of graphene for 3D image reconstruction of proteins using cryo-EM	National Phase	Application	Israel	243747	07/08/2014		
A813/2898	Hydrogenation of graphene for 3D image reconstruction of proteins using cryo-EM	National Phase	Application	China	201480055929.2	07/08/2014		
A813/2899	Method for producing gold EM grids	National Phase	Application	South Africa	2016/00920	12/08/2014		
A813/2899	Method for producing gold EM grids	National Phase	Application	Israel	243880	12/08/2014		
A813/2899	Method for producing gold EM grids	National Phase	Application	Japan	2016-533951	12/08/2014		

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
A813/2899	Method for producing gold EM grids	National Phase	Application	Singapore	11201600771U	12/08/2014		
A813/2899	Method for producing gold EM grids	National Phase	Application	Hong Kong	16112904.2	12/08/2014		
A813/2899	Method for producing gold EM grids	National Phase	Application	United States	14/911,723	12/08/2014		
A813/2899	Method for producing gold EM grids	National Phase	Application	Australia	2014307715	12/08/2014		
A813/2899	Method for producing gold EM grids	National Phase	Application	Canada	2,919,961	12/08/2014		
A813/2899	Method for producing gold EM grids	National Phase	Application	Europe	14750632.3	12/08/2014		
A813/2899	Method for producing gold EM grids	National Phase	Application	China	201480049902.2	12/08/2014		
A813/2913	Thermostabilised version of SERT in a cocaine-bound confirmation	National Phase	Application	United States	14/776908	13/03/2014		
A813/2913	Thermostabilised version of SERT in a cocaine-bound confirmation	National Phase	Application	Europe	14713889.5	13/03/2014		
A813/2929	MitoG and MitoGamide for the protection of hyperglycaemia	National Phase	Application	New Zealand	719705	21/11/2014		
A813/2929	MitoG and MitoGamide for the protection of hyperglycaemia	National Phase	Application	Hong Kong	16114224.1	21/11/2014		
A813/2929	MitoG and MitoGamide for the protection of hyperglycaemia	National Phase	Application	India	201617017578	21/11/2014		
A813/2929	MitoG and MitoGamide for the protection of hyperglycaemia	National Phase	Application	United States	15,037,941	21/11/2014		
A813/2929	MitoG and MitoGamide for the protection of hyperglycaemia	National Phase	Application	Australia	2014351802	21/11/2014		
A813/2929	MitoG and MitoGamide for the protection of hyperglycaemia	National Phase	Application	Japan	2016-528890	21/11/2014		
A813/2929	MitoG and MitoGamide for the protection of hyperglycaemia	National Phase	Application	Europe	14818889.9	21/11/2014		
A813/2929	MitoG and MitoGamide for the protection of hyperglycaemia	National Phase	Application	Singapore	11201603485T	21/11/2014		
A813/2929	MitoG and MitoGamide for the protection of hyperglycaemia	National Phase	Application	South Africa	2016/03129	21/11/2014		
A813/2929	MitoG and MitoGamide for the protection of hyperglycaemia	National Phase	Application	China	201480063625.0	21/11/2014		

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
A813/2929	MitoG and MitoGarnide for the protection of hyperglycaemia	National Phase	Application	Canada	2,931,000	21/11/2014		
A813/3035	Inhibition of ischaemic succinate accumulation	National Phase	Application	United States	15/322,939	03/07/2015		
A813/3035	Inhibition of ischaemic succinate accumulation	National Phase	Application	Hong Kong	17106079.2	03/07/2015		
A813/3035	Inhibition of ischaemic succinate accumulation	National Phase	Application	Australia	2015282424	03/07/2015		
A813/3035	Inhibition of ischaemic succinate accumulation	National Phase	Application	United Kingdom	1411937.4	03/07/2014		
A813/3035	Inhibition of ischaemic succinate accumulation	National Phase	Application	China	20159003346.8	03/07/2015		
A813/3035	Inhibition of ischaemic succinate accumulation	National Phase	Application	Singapore	11201610588U	03/07/2015		
A813/3035	Inhibition of ischaemic succinate accumulation	National Phase	Application	Europe	15736028.0	03/07/2015		
A813/3035	Inhibition of ischaemic succinate accumulation	National Phase	Application	Canada	2,953,709	03/07/2015		
A813/3035	Inhibition of ischaemic succinate accumulation	National Phase	Application	South Africa	2016/08844	03/07/2015		
A813/3035	Inhibition of ischaemic succinate accumulation	National Phase	Application	New Zealand	727725	03/07/2015		
A813/3035	Inhibition of ischaemic succinate accumulation	National Phase	Application	Japan	JF2016-574359	03/07/2015		
A813/3045	Tissue-specific and Developmental Stage-specific Protein Labeling and Identification in an Animal v	National Phase	Application	Brazil	BR112016019179-0	10/03/2015		
A813/3045	Tissue-specific and Developmental Stage-specific Protein Labeling and Identification in an Animal v	National Phase	Application	South Korea	10-2016-7025032	10/03/2015		
A813/3045	Tissue-specific and Developmental Stage-specific Protein Labeling and Identification in an Animal v	National Phase	Application	India	201617027126	10/03/2015		
A813/3045	Tissue-specific and Developmental Stage-specific Protein Labeling and Identification in an Animal v	National Phase	Application	Canada	2,941,069	10/03/2015		

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
	Identification in an Animal v							
A813/3045	Tissue-specific and Developmental Stage-specific Protein Labeling and Identification in an Animal v	National Phase	Application	Hong Kong	17104962.7	10/03/2015		
A813/3045	Tissue-specific and Developmental Stage-specific Protein Labeling and Identification in an Animal v	National Phase	Application	China	201580013864X	10/03/2015		
A813/3045	Tissue-specific and Developmental Stage-specific Protein Labeling and Identification in an Animal v	National Phase	Application	Japan	2016-554887	10/03/2015		
A813/3045	Tissue-specific and Developmental Stage-specific Protein Labeling and Identification in an Animal v	National Phase	Application	United States	15/124,632	10/03/2015		
A813/3045	Tissue-specific and Developmental Stage-specific Protein Labeling and Identification in an Animal v	National Phase	Application	Europe	15711271.5	10/03/2015		
A813/3084	optimised unnatural amino acid incorporation in mammalian cell background	National Phase	Application	United States	15/521,103	27/10/2015		
A813/3084	optimised unnatural amino acid incorporation in mammalian cell background	National Phase	Application	Brazil	BR112017008108-3	27/10/2015		
A813/3084	optimised unnatural amino acid incorporation in mammalian cell background	National Phase	Application	Canada	2985085	27/10/2015		
A813/3084	optimised unnatural amino acid incorporation in mammalian cell background	National Phase	Application	India	201717013653	27/10/2015		
A813/3084	optimised unnatural amino acid incorporation in mammalian cell background	National Phase	Application	China	2015800587846	27/10/2015		
A813/3084	optimised unnatural amino acid incorporation in mammalian cell background	National Phase	Application	United Kingdom	1419109.2	27/10/2014		

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
A813/3084	optimised unnatural amino acid incorporation in mammalian cell background	National Phase	Application	South Korea	10-2017-7014048	27/10/2015		
A813/3084	optimised unnatural amino acid incorporation in mammalian cell background	National Phase	Application	Hong Kong	17109754.6	26/09/2017		
A813/3084	optimised unnatural amino acid incorporation in mammalian cell background	National Phase	Application	Japan	JP2017-519813	27/10/2015		
A813/3084	optimised unnatural amino acid incorporation in mammalian cell background	National Phase	Application	Europe	15794622.9	27/10/2015		
A813/3089	bi specific peptide	National Phase	Application	Europe	15807980.6	01/12/2015		
A813/3133	Biomarkers for childhood TB	PCT	Application	United Kingdom	GB1602305.3	09/02/2016		
A813/3138	Cu nanoparticles for wound healing	National Phase	Application	China	201680037392.6	22/04/2016		
A813/3138	Cu nanoparticles for wound healing	National Phase	Application	Europe	16717670.0	22/04/2016		
A813/3138	Cu nanoparticles for wound healing	National Phase	Application	Japan	2017-555479	22/04/2016		
A813/3138	Cu nanoparticles for wound healing	National Phase	Application	Singapore	11201708618W	22/04/2016		
A813/3138	Cu nanoparticles for wound healing	National Phase	Application	United States	15/567.419	22/04/2016		
A813/3138	Cu nanoparticles for wound healing	National Phase	Application	Canada	2983651	22/04/2016		
A813/3161	Cu nanoparticles for wound healing	National Phase	Application	United Kingdom	1517893.2	09/10/2015		
A813/3165	Ethanol recovery of iHAT for large scale manufacture	PCT	Application	United Kingdom	1706945.1	02/05/2017		
A813/3182	Modified rabies virus as a drug delivery system	Priority	Application	United Kingdom	PCT/EP2017/06924	29/07/2017		
A813/3182	Device for making sample grids for electron microscopy	PCT	Application	PCT	1613173.2	29/07/2016		
A813/3182	Device for making sample grids for electron microscopy	PCT	Application	United Kingdom	PCT/GB2017/05218	27/07/2017		
A813/3191	REXER - large scale genetic transfer/modification methodology	PCT	Application	PCT	PCT/EP2017/05769	31/03/2017		
A813/3192	Ferri trimalic synthesis from ligand modified ferric hydroxides	PCT	Application	PCT	1			

46617.4
Classification: Confidential

35

WORK/31069583iv.3

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
A813/3192	Ferric trimaltoï synthesis from ligand-modified ferric hydroxides	PCT	Application	United Kingdom	1605470.2	31/03/2016		
A813/3210	Ferric trimaltoï as an anti-cancer drug	PCT	Application	United Kingdom	1605474.4	31/03/2016		
A813/3210	Ferric trimaltoï as an anti-cancer drug	PCT	Application	PCT	PCT/EP2017/05770 ₅	31/03/2017		
A813/3212	Ferric trimaltoï synthesis from ferrous hydroxides	PCT	Application	PCT	PCT/EP2017/05770 ₃	31/03/2017		
A813/3212	Ferric trimaltoï synthesis from ferrous hydroxides	PCT	Application	United Kingdom	1605501.4	31/03/2016		
A813/3213	Ferric trimaltoï synthesis from elemental iron	PCT	Application	PCT	PCT/EP2017/05770 ₂	31/03/2017		
A813/3213	Ferric trimaltoï synthesis from elemental iron	PCT	Application	United Kingdom	1605493.4	31/03/2016		
A813/3217	Nanosilica for T cell activation - part 2	PCT	Application	PCT	PCT/EP2017/07018 ₃	09/08/2017		
A813/3217	Nanosilica for T cell activation - part 2	PCT	Application	United Kingdom	1701827.6	03/02/2017		
A813/3221	HIV 1 dNTP pore as a novel therapeutic approach	PCT	Application	PCT	PCT/EP2017/06217 ₉	19/05/2017		
A813/3264	New diagnostic for detection of FMVD infections	Priority	Application	United Kingdom	1719236.0	20/11/2017		
A813/3266	Sugar modified pro-drugs as senolytics	Priority	Application	United Kingdom	1708458.3	26/05/2017		
A813/3267	Compounds as senolytics	Priority	Application	United Kingdom	1708456.7	26/05/2017		
A813/3274	Copper maltoï and PEG assemblies as antimicrobials	PCT	Application	United Kingdom	1701944.9	06/02/2017		
A813/3274	Copper maltoï and PEG assemblies as antimicrobials	PCT	Application	PCT	PCT/EP2018/05295 ₆	06/02/2018		
A813/3280	Anti-viral engineered antibodies	PCT	Application	PCT	PCT/US2017/02222 ₅	14/03/2017		
A813/3282	Cell Penetrating Peptides for SMA	PCT	Application	PCT	PCT/GE2018/05042 ₃	16/02/2019		
A813/3282	Cell Penetrating Peptides for SMA	PCT	Application	United Kingdom	1602598.1	16/02/2018		
A813/3312	Helophosphatase	Priority	Application	United Kingdom	1709927.6	21/06/2017		

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant date	Grant number
A813/3318	In vitro Gametogenesis	Priority	Application	United Kingdom	1721724.1	22/12/2017		
A813/355	MASP-2	National Phase	Application	United States	11032149	11/01/2005	13/06/2006	7060267
A813/355	MASP-2	National Phase	Application	United States	13359348	26/01/2012	08/10/2013	8551790
A813/355	MASP-2	National Phase	Application	United States	09/874,198	04/06/2001	29/11/2005	6,969,601
A813/355	MASP-2	National Phase	Application	United States	14031377	19/09/2013	13/09/2016	9441262
A813/355	MASP-2	National Phase	Application	United States	09874238	04/06/2001	01/08/2006	7083786
A813/355	MASP-2	National Phase	Application	United States	15227479	03/08/2016		
A813/355	MASP-2	National Phase	Provisional	United States	80042678	03/04/2007		
A813/930	Winter II/Library Construction	National Phase	Continuation	United States	09722,364	28/11/2000	08/04/2003	6,545,142
A813/930	Winter II/Library Construction	National Phase	Continuation	United States	09/470,091	13/11/1989	19/06/2001	6,248,516
A813/930	Winter III/Library Construction	National Phase	Continuation	United States	07/941,762	04/09/1992	18/09/2001	6,291,161
A813/930	Winter III/Library Construction	National Phase	Continuation	United States	07/933,959	21/08/1992	18/09/2001	6,291,159
A813/930	Winter III/Library Construction	National Phase	Continuation	United States	07/933,958	21/08/1992	18/09/2001	6,291,158
A813/930	Winter III/Library Construction	National Phase	Application	United States	07796,805	25/11/1991		
A813/930	Winter III/Library Construction	National Phase	Continuation	United States	07/941,761	25/11/1992	18/09/2001	6,291,160
A813/930	Winter III/Library Construction	National Phase	Divisional	United States	09/726,653	28/11/2000	01/01/1900	6,680,192
A813/930	Winter III/Library Construction	National Phase	Application	United Kingdom	8909217.5	22/04/1989		

46617.4
Classification: Confidential

Part B - Exclusively Licensed

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant number	Grant date
A813/0895	Campath-1	National Phase	Application	Germany	2001199051	10/02/1989	DE10199051	04/05/2005
A813/0895	Campath-1	National Phase	Divisional	United States	08/407,820	21/03/1995	6,569,430	27/05/2003
A813/0895	Campath-1	National Phase	Application	United States	08/235,705	29/04/1994	5,846,534	08/12/1998
A813/0930	Winter H/Library Construction (phage)	National Phase	Application	Norway	90.3059	13/11/1989		
A813/0930	Winter H/Library Construction (phage)	National Phase	Continuation	United States	12/127,237	13/11/1989		
A813/0930	Winter H/Library Construction (phage)	National Phase	Application	United States	07/971,957	01/08/1993		
A813/0930	Winter H/Library Construction (phage)	National Phase	Application	Finland	903489	13/11/1989		
A813/0930	Winter H/Library Construction (phage)	National Phase	Divisional	United States	10/910,463	02/08/2009	7,189,841	19/03/2007
A813/0930	Winter H/Library Construction (phage)	National Phase	Application	United States	10/290,252	08/11/2002	7,308,907	11/12/2007
A813/1046	Phage Antibody Screening (McCafferty)	National Phase	Divisional	United States	10/603,822	18/03/2004	7,732,377	08/06/2010
A813/1046	Phage Antibody Screening (McCafferty)	National Phase	Application	Canada	2086936	10/07/1991	2086936	16/08/2005
A813/1046	Phage Antibody Screening (McCafferty)	National Phase	Application	Australia	8221691	10/07/1991	664155	27/02/1996
A813/1046	Phage Antibody Screening (McCafferty)	National Phase	Application	South Korea	93-700061	10/07/1991	0222326	01/10/1999
A813/1046	Phage Antibody Screening (McCafferty)	National Phase	Application	Japan	19910512353	10/07/1991	3176917	13/06/2001
A813/1046	Phage Antibody Screening (McCafferty)	National Phase	Continuation	United States	09/726,219	26/11/2000	6806079	19/10/2004
A813/1046	Phage Antibody Screening (McCafferty)	National Phase	Continuation	United States	09/169,673	20/11/1998	7,063,943	20/06/2006
A813/1046	Phage Antibody Screening (McCafferty)	National Phase	Continuation	United States	09/196,822	20/11/1989	6916605	12/07/2005

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant number	Grant date
A813/1046	Phage Antibody Screening (McCafferty)	National Phase	Application	United States	07/971,857	08/01/1993	5,969,108	19/10/1999
A813/1046	Phage Antibody Screening (McCafferty)	National Phase	Continuation	United States	08/484,893	07/06/1995	6,172,197	09/01/2001
A813/1205	Zinc finger binding proteins	National Phase	Application	United Kingdom	9422534.9	06/11/1994	RE45,721	06/10/2015
A813/1205	Zinc finger binding proteins	National Phase	Application	United States	10/400,017	25/03/2003	RE42,150	15/02/2011
A813/1205	Zinc finger binding proteins	National Phase	Application	United States	11/500,162	07/08/2006	6,013,453	11/01/2000
A813/1205	Zinc finger binding proteins	National Phase	Application	United States	09/139,752	25/08/1998	RE42,211	08/03/2011
A813/1205	Zinc finger binding proteins	National Phase	Divisional	United States	10/397,930	25/03/2003		
A813/1205	Zinc finger binding proteins	National Phase	Application	United Kingdom	9514698.1	18/07/1995		
A813/1205	Zinc finger binding proteins	National Phase	Application	United Kingdom	9418880.4	20/08/1994		
A813/1205	Zinc finger binding proteins	National Phase	Application	United States	10/309,578	03/12/2002		
A813/1205	Zinc finger binding proteins	National Phase	Application	United States	08/793,408	17/08/1995	6,007,986	28/12/1999
A813/1205	Zinc finger binding proteins	National Phase	Application	United States	10/033,129	27/12/2001	RE 39,229	08/08/2006
A813/1205	Zinc finger binding proteins	National Phase	Application	Europe	95928576.8	17/08/1995	EP 0781331	03/09/2008
A813/1205	Zinc finger binding proteins	National Phase	Application	Australia	3228195	17/08/1995	668152	18/02/1999
A813/1205	Zinc finger binding proteins	National Phase	Application	Canada	2,196,419	17/08/1995	CA2196419	21/08/2007
A813/1205	Zinc finger binding proteins	National Phase	Divisional	Australia	10037/99	17/08/1995	726759	23/11/2000
A813/1205	Zinc finger binding proteins	National Phase	Application	Japan	19960507857	17/08/1995	JP4118327	16/07/2008
A813/1205	Zinc finger binding proteins	National Phase	Divisional	Europe	08015296.1	17/08/1995	2022856	14/09/2011
A813/1361	Nucleic Acid Binding Proteins	National Phase	Application	Japan	1998-550158	26/05/1998		
A813/1361	Nucleic Acid Binding Proteins	National Phase	Continuation	United States	11/515,369	31/08/2006	7,759,059	20/07/2010
A813/1361	Nucleic Acid Binding Proteins	National Phase	Continuation	United States	10/853,437	24/05/2004	7,241,574	10/07/2007
A813/1361	Nucleic Acid Binding Proteins	National Phase	Application	United States	09/424,488	26/05/1998	5,866,997	15/03/2005
A813/1361	Nucleic Acid Binding Proteins	National Phase	Application	Canada	2,290,886	26/05/1998	2290886	31/08/2010
A813/1361	Nucleic Acid Binding Proteins	National Phase	Application	Australia	75456/98	26/05/1998	732017	26/07/2001
A813/1361	Nucleic Acid Binding Proteins	National Phase	Application	Europe	96922967.9	26/05/1998	0963351	30/04/2008
A813/1388	Inhibition of Tau - Tau Association	National Phase	Application	United States	08/913,915	25/03/1997	6,376,205	23/04/2002
A813/1388	Inhibition of Tau - Tau Association	National Phase	Application	Canada	CA19962215397	25/03/1996	2215397	02/02/2008
A813/1409	Screening System	National Phase	Continuation In	United States	09/851,271	09/11/1999	6,733,970	11/05/2004

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant number	Grant date
A813/1409	Screening System	National Phase	Part	Japan	2000581055	09/11/1999		
A813/1409	Screening System	National Phase	Application	New Zealand	511564	09/11/1999	511564	03/02/2003
A813/1420	Methylation	National Phase	Application	New Zealand	506987	17/03/1999	506987	12/05/2003
A813/1420	Methylation	National Phase	Application	Canada	2,323,064	17/03/1999	2323064	31/05/2011
A813/1420	Methylation	National Phase	Application	Europe	99910512.5	17/03/1999	1064369	16/06/2006
A813/1420	Methylation	National Phase	Application	Australia	29449/99	17/03/1999	751467	28/11/2002
A813/1420	Methylation	National Phase	Application	United States	09/646,353	17/03/1999	6,977,154	20/12/2005
A813/1438	Nucleic Acid Binding Proteins	National Phase	Continuation	United States	11/496,962	26/05/1998	8,617,807	31/12/2013
A813/1438	Nucleic Acid Binding Proteins	National Phase	Continuation	United States	10/632,735	26/05/1998	7,241,573	10/07/2007
A813/1438	Nucleic Acid Binding Proteins	National Phase	Application	Europe	98922984.6	26/05/1998	0983350	30/04/2008
A813/1438	Nucleic Acid Binding Proteins	National Phase	Application	United States	09/424,487	26/05/1998	6,746,838	06/06/2004
A813/1438	Nucleic Acid Binding Proteins	National Phase	Application	Canada	2,290,717	26/05/1998	2,290,717	05/01/2010
A813/1439	Nucleic Acid Binding Polypeptide Library	National Phase	Application	United States	11/514,671	26/05/1998	7,700,523	20/04/2010
A813/1439	Nucleic Acid Binding Polypeptide Library	National Phase	Application	United States	11/514,850	26/05/1998	8,618,024	31/12/2013
A813/1439	Nucleic Acid Binding Polypeptide Library	National Phase	Application	Europe	98922963.8	26/05/1998	EP09883349	13/04/2016
A813/1439	Nucleic Acid Binding Polypeptide Library	National Phase	Application	Australia	1998-75422	26/05/1998	737756	18/12/2001
A813/1439	Nucleic Acid Binding Polypeptide Library	National Phase	Application	Japan	2012-129566	26/05/1998	JPS795749	14/10/2015
A813/1439	Nucleic Acid Binding Polypeptide Library	National Phase	Application	Canada	2,290,720	26/05/1998	2,290,720	15/07/2008
A813/1467	Method For Generating Diversity	National Phase	Application	United Kingdom	9901141.3	19/01/1999		
A813/1467	Method For Generating Diversity	National Phase	Application	United Kingdom	9822104.7	09/10/1998		
A813/1467	Method For Generating Diversity	National Phase	Application	United Kingdom	9913435.5	09/06/1999		
A813/1467	Method For Generating Diversity	National Phase	Divisional	Europe	09180683.6	08/10/1999	2204447	01/06/2016
A813/1467	Method For Generating Diversity	National Phase	Application	Europe	99947775.5	08/10/1999	1117774	30/12/2009 10:36

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant number	Grant date
A813/1467	Method For Generating Diversity	National Phase	Application	Canada	2,346,927	08/10/1999	2,346,927	22/09/2009
A813/1467	Method For Generating Diversity	National Phase	Application	Japan	2000-576002	08/10/1999	4302894	01/05/2009 16-04
A813/1467	Method For Generating Diversity	National Phase	Application	Australia	61142/99	08/10/1999	0776049	09/12/2004
A813/1467	Method For Generating Diversity	National Phase	Continuation in Part	United States	10/146,505	15/05/2002	7,122,339	17/10/2006 12-06
A813/1490	Intracellular Selection	National Phase	Application	United States	09/936,170	10/03/2000	7,569,390	04/09/2009
A813/1490	Intracellular Selection	National Phase	Application	Europe	00909465.7	10/03/2000	1166121	14/12/2011
A813/1490	Intracellular Selection	National Phase	Divisional	United States	12/533,614	31/07/2009 10-12	7,897,347	01/03/2011
A813/1500	Quadruplexes	National Phase	Application	United States	09/614,679	12/07/2000	6,492,117	10/12/2002
A813/1530	Molecules	National Phase	Continuation in Part	United States	09/732,348	07/12/2000	7,282,055	29/08/2007
A813/1530	Molecules	National Phase	Application	Japan	2001500747	30/05/2000		
A813/1571	Linkers	National Phase	Application	United Kingdom	0013102.9	30/05/2000		
A813/1571	Linkers	National Phase	Application	United Kingdom	0013104.5	30/05/2000		
A813/1571	Linkers	National Phase	Application	United Kingdom	0013103.7	30/05/2000		
A813/1571	Linkers	National Phase	Application	United States	10/198,677	19/01/2001	7,851,216	14/12/2010
A813/1571	Linkers	National Phase	Application	United Kingdom	0001582.6	24/01/2000		
A813/1571	Linkers	National Phase	Application	Canada	2398155	19/01/2001	2398155	19/07/2011
A813/1571	Linkers	National Phase	Application	Europe	01901275.4	19/01/2001	1250424	28/02/2007
A813/1571	Linkers	National Phase	Application	Australia	2001226935	19/01/2001	2001226935	19/10/2006
A813/1585	Crystal Structure	National Phase	Application	United Kingdom	0117142.0	14/07/2001	2368067	11/11/2004
A813/1585	Crystal Structure	National Phase	Continuation in Part	United States	09/953,814	17/09/2001	7,079,956	18/07/2006
A813/1638	Viral Fingers	National Phase	Application	United Kingdom	0013106	30/05/2000		
A813/1638	Viral Fingers	National Phase	Application	United Kingdom	0101446.3	19/01/2001		
A813/1638	Viral Fingers	National Phase	Application	United Kingdom	0011068.4	08/05/2000		
A813/1667	Intrabodies	National Phase	Application	United States	10/771,257	03/02/2004	7,608,453	27/10/2009
A813/1678	Crystal Structure	National Phase	Application	United States	09/904,779	13/07/2001	6,925,394	02/03/2005
A813/1678	Crystal Structure	National Phase	Application	Europe	01306080.3	13/07/2001	1172374	22/11/2006

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant number	Grant date
A813/1678	Crystal Structure	National Phase	Continuation in Part	United States	09/953,607	17/09/2001	7,606,670	20/10/2009 14:36
A813/1706	Activation Induced Deaminase (AID)	National Phase	Divisional	United States	12/911,292	09/05/2003	8288160	16/10/2012
A813/1706	Activation Induced Deaminase (AID)	National Phase	Application	United Kingdom	0217519.8	29/07/2002		
A813/1708	Activation Induced Deaminase (AID)	National Phase	Divisional	United States	13/606,696	07/09/2012		
A813/1708	Activation Induced Deaminase (AID)	National Phase	Application	United Kingdom	0213751.1	14/06/2002		
A813/1708	Activation Induced Deaminase (AID)	National Phase	Application	Europe	03722898.4	09/05/2003	1506288	17/04/2013
A813/1708	Activation Induced Deaminase (AID)	National Phase	Continuation	United States	10/985,321	10/11/2004	7,820,442	26/10/2010
A813/1792	FC Fusion	National Phase	Application	Europe	1581559	13/07/2005	1581559	30/08/2010
A813/1792	FC Fusion	National Phase	Application	Hong Kong	08104686.3	28/04/2006		
A813/1792	FC Fusion	National Phase	Application	United Kingdom	0290303.2	27/12/2002		
A813/1792	FC Fusion	National Phase	Application	Japan	20130142295	08/07/2013		
A813/1792	FC Fusion	National Phase	Application	Australia	20030295139	24/12/2003	2003295139	01/05/2012
A813/1792	FC Fusion	National Phase	Application	Canada	20032511959	24/12/2003	2511959	16/12/2014
A813/1803	Compartmentalised Combinatorial Chemistr	National Phase	Application	United States	11/238,257	29/09/2005	7,718,578	18/05/2010 10:02
A813/1803	Compartmentalised Combinatorial Chemistry	National Phase	Application	Japan	2014-144285	31/03/2004	6100736	22/03/2017
A813/1803	Compartmentalised Combinatorial Chemistry	National Phase	Application	Europe	12172466.0	31/03/2004		
A813/1803	Compartmentalised Combinatorial Chemistr	National Phase	Application	Europe	04724636.6	31/03/2004 09:28		
A813/1803	Compartmentalised Combinatorial Chemistr	National Phase	Application	Canada	2520630	31/03/2004	2520630	03/11/2015
A813/1803	Compartmentalised Combinatorial Chemistr	National Phase	Application	Australia	2004226699	31/03/2004	2004/226699	22/03/2012
A813/1804	Selection By Compartmentalised Screening	National Phase	Application	Japan	2014-246570	31/03/2004		

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant number	Grant date
A813/1804	Selection By Compartmentalised Screening	National Phase	Application	United States	15/331,445	21/10/2016		
A813/1804	Selection By Compartmentalised Screening	National Phase	Continuation	United States	15/655,612	27/12/2017		
A813/1804	Selection By Compartmentalised Screening	National Phase	Continuation	United States	11/238,258	29/09/2005	9448172	20/09/2016
A813/1804	Selection By Compartmentalised Screening	National Phase	Continuation	United States	13/208,614	12/08/2011		
A813/1804	Selection By Compartmentalised Screening	National Phase	Divisional	Europe	11167339.8	31/03/2004		
A813/1804	Selection By Compartmentalised Screening	National Phase	Application	Europe	04724631.9	31/03/2004	1608976	05/09/2012
A813/1804	Selection By Compartmentalised Screening	National Phase	Application	Canada	2,520,548	31/03/2004	2520548	19/01/2016
A813/1804	Selection By Compartmentalised Screening	National Phase	Application	Australia	2004225691	31/03/2004	2004-225691	07/10/2010
A813/1804	Selection By Compartmentalised Screening	National Phase	Divisional	Australia	2010224352	31/03/2004	2010-224352	22/12/2011
A813/1804	Selection By Compartmentalised Screening	National Phase	Divisional	Europe	12195655.8	12/10/2005	2602018	27/04/2016
A813/1804	Selection By Compartmentalised Screening	National Phase	Application	Europe	05792856.6	12/10/2005	1842067	14/12/2016
A813/1857	Method For Generating Diversity 2	National Phase	Application	Europe	02735612.0	11/06/2002	1399016	28/08/2013
A813/1857	Method For Generating Diversity 2	National Phase	Application	Canada	2,449,264	11/06/2002	2,449,264	29/05/2012
A813/1857	Method For Generating Diversity 2	National Phase	Application	United States	10733,532	11/06/2002	7,388,259	06/05/2008
A813/1857	Method For Generating Diversity 2	National Phase	Application	Japan	2003-503750	11/06/2002	4418668	04/12/2009 15-30
A813/1857	Method For Generating Diversity 2	National Phase	Application	Australia	2002310621	11/06/2002	2002310621	17/01/2006
A813/1897	Compartmentalised Screening	National Phase	Application	United States	11/665,145	12/10/2005	9496759	22/11/2016
A813/1897	Compartmentalised Screening	National Phase	Divisional	Europe	16194377.4	12/10/2005		
A813/1897	Compartmentalised Screening	National Phase	Application	Europe	04724631.9	31/03/2004	1608976	05/09/2012
A813/1897	Compartmentalised Screening	National Phase	Application	Japan	2007-536255	12/10/2005	4829240	22/09/2011
A813/1897	Compartmentalised Screening	National Phase	Divisional	Europe	12195655.8	12/10/2005	2602018	27/04/2016

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant number	Grant date
A813/1897	Compartmentalised Screening	National Phase	Application	Europe	05792856.6	12/10/2005	1842067	14/12/2016
A813/1897	Compartmentalised Screening	National Phase	Application	Canada	2,582,465	12/10/2005	2582465	16/09/2014
A813/1900	Directed Evolution of Nucleic Acids	National Phase	Divisional	Europe	15163413.6	10/10/2005		
A813/1900	Directed Evolution of Nucleic Acids	National Phase	Continuation	United States	15/012,209	10/10/2005		
A813/1900	Directed Evolution of Nucleic Acids	National Phase	Continuation	United States	15/588,210	10/10/2005		
A813/1900	Directed Evolution of Nucleic Acids	National Phase	Application	Canada	2,582,476	10/10/2005		
A813/1900	Directed Evolution of Nucleic Acids	National Phase	Continuation	United States	13/692,615	10/10/2005	9,186,643	17/11/2015
A813/1900	Directed Evolution of Nucleic Acids	National Phase	Application	United States	10/961,695	08/10/2004	7968287	28/06/2011
A813/1900	Directed Evolution of Nucleic Acids	National Phase	Application	United States	US20160012209	01/02/2016		
A813/1900	Directed Evolution of Nucleic Acids	National Phase	Application	Japan	2015-235625	02/04/2013		
A813/1900	Directed Evolution of Nucleic Acids	National Phase	Application	United States	11/665,030	10/10/2005	9,029,083	12/05/2015
A813/1900	Directed Evolution of Nucleic Acids	National Phase	Continuation	United States	13/693,356	10/05/2005	8,871,444	28/10/2014
A813/1900	Directed Evolution of Nucleic Acids	National Phase	Application	Europe	10179380.0	10/10/2005	2267163	15/04/2015
A813/1900	Directed Evolution of Nucleic Acids	National Phase	Application	Europe	05792245.2	10/10/2005	1805924	05/10/2011
A813/1900	Directed Evolution of Nucleic Acids	National Phase	Divisional	Europe	10179420.4	10/10/2005	2270236	04/03/2015
A813/1900	Directed Evolution of Nucleic Acids	National Phase	Divisional	Europe	10179400.6	10/10/2005	2270235	01/10/2014
A813/1900	Directed Evolution of Nucleic Acids	National Phase	Application	Japan	2013-077141	02/04/2013	5903067	16/03/2016
A813/1901	Compartmentalised Combinatorial Chemistry	National Phase	Divisional	Europe	12173230.9	12/10/2005		
A813/1901	Compartmentalised Combinatorial Chemistry	National Phase	Application	United States	11/238,257	29/09/2005	7/18578	18/06/2015
A813/1901	Compartmentalised Combinatorial Chemistr	National Phase	Application	Europe	05792864.0	12/10/2005		
A813/1901	Compartmentalised Combinatorial Chemistr	National Phase	Application	Canada	2,582,470	12/10/2005	2682470	20/08/2013
A813/1901	Compartmentalised Combinatorial Chemistr	National Phase	Application	Japan	2007-536257	12/10/2005	5509412	04/04/2014
A813/1935	Fluorescence Readout Device	National Phase	Application	United States	11/727,935	29/09/2007	7,776,536	17/08/2010
A813/1964	Novel synthetic route for caged GABA	National Phase	Application	United States	11/507,961	22/08/2006	7,737,169	15/06/2010
A813/1985	Zinc Fingers	National Phase	Divisional	United States	14/859,596	21/09/2015		

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant number	Grant date
A813/1985	Zinc Fingers	National Phase	Application	Japan	2009-546588	19/12/2006		
A813/1985	Zinc Fingers	National Phase	Application	Australia	20060928193	19/12/2006	2006326193	21/02/2013
A813/1985	Zinc Fingers	National Phase	Application	Europe	06820567.3	19/12/2006	1974034	20/09/2013
A813/1985	Zinc Fingers	National Phase	Application	United States	12/143,836	23/06/2008 09:57	9,139,628	22/09/2015
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Brazil	PI0810418.2	17/04/2008 16:20		
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Egypt	PCT/NA/1529/2009	17/04/2008		
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Sri Lanka	15573	10/03/2010		
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Guatemala	A 2009-00271	17/04/2008 11:22		
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	El Salvador	E-3395-2009 P9579-2009	17/04/2008		
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Brunei	HER120140023	07/04/2009	MY-148451-A	29/04/2014
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Ecuador	SP-09-9726	10/11/2009		
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Ukraine	2009 11796	17/04/2008	100377	25/12/2012
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Mexico	MX/a/2009/01123 4	17/04/2008	292146	14/11/2011
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Canada	2,684,492	17/04/2008	2,684,492	24/11/2015
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	New Zealand	NZ20080561178	17/04/2008 15:41	581178	07/05/2012
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Indonesia	W-05200903228	17/04/2008	IP000041982	29/06/2016
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Honduras	2009-0030338	17/04/2008	5187	02/03/2012
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	South Africa	2009/07726	17/04/2008 14:57	2009/07726	26/01/2011
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Nicaragua	2009000189	17/04/2008	2415RPI	09/11/2015
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Japan	2010-503589	17/04/2008	5366930	20/09/2013
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Israel	201552	17/04/2008	201552	01/12/2015
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Malaysia	PI020094358	17/04/2008 15:18	MY-148451-A	30/04/2013
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	United States	12/596,053	17/04/2008	8,206,717	26/06/2012

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant number	Grant date
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Eurasia	200901421	11-17	018073	30/05/2013
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Singapore	200906394-1	17/04/2008	156295	31/05/2012
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	South Korea	1020097023939	17/04/2008	10-1505861	17/03/2016
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Australia	2008240436	17/04/2008 11-15	2006240436	30/06/2011
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	China	200880020620.4	17/04/2008 11-19	ZL20088002060.4	18/10/2013
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Europe	08737025.0	17/04/2008 11-50	2144534	24/08/2016
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Colombia	09-123670	17/04/2008 11-04	2667	01/04/2013
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Costa Rica	11079	17/04/2008	3243	18/12/2015
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Nigeria	NGC2009547	17/04/2008	NG/C/2009/547	15/09/2010
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	India	7128/DELNP/2009	17/04/2008	264519	01/01/2015
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Vietnam	1-2009-02458	17/04/2008 15-16	12363	07/02/2014
A813/2048	IL-25 Ab against allergic reactions	National Phase	Application	Philippines	1-2009-501995	17/04/2008	12009501995	03/10/2014
A813/2213	Phosphate Binder	National Phase	Application	India	545/KCLNP/2011	05/08/2009		
A813/2213	Phosphate Binder	National Phase	Application	Brazil	P10917503-2	05/08/2009		
A813/2213	Phosphate Binder	National Phase	Application	Japan	2011521635	05/08/2009	5805532	11/09/2015
A813/2213	Phosphate Binder	National Phase	Application	South Korea	10-2011-7004981	05/08/2009	10-1653423	26/08/2016
A813/2213	Phosphate Binder	National Phase	Application	Australia	2009276906	05/08/2009	2009276906	26/02/2015
A813/2213	Phosphate Binder	National Phase	Application	United Kingdom	0913684.7	05/08/2009 15-05	2462374	22/12/2010
A813/2213	Phosphate Binder	National Phase	Application	Hong Kong	11107652.9	05/08/2009	HK 1153402	04/08/2017
A813/2213	Phosphate Binder	National Phase	Application	Mexico	MX/A/2011/001258	05/08/2009	294631	13/01/2012
A813/2213	Phosphate Binder	National Phase	Application	Eurasia	201170116	05/08/2009	021705	31/08/2015
A813/2213	Phosphate Binder	National Phase	Application	Singapore	201100555-0	05/08/2009	168355	30/11/2011
A813/2213	Phosphate Binder	National Phase	Application	Israel	210913	05/08/2009	210913	01/11/2014

Rei	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant number	Grant date
A813/2213	Phosphate Binder	National Phase	Application	Europe	09764878.2	05/08/2009	2320884	13/07/2016
A813/2213	Phosphate Binder	National Phase	Application	China	200980134870.5	05/08/2009	ZL200980134870.5	13/05/2015
A813/2213	Phosphate Binder	National Phase	Application	South Africa	2011/00821	05/08/2009	2011/00821	28/09/2011
A813/2213	Phosphate Binder	National Phase	Application	Canada	2732226	05/08/2009	CA 2732226	12/09/2017
A813/2213	Phosphate Binder	National Phase	Application	United States	12/536,014	05/08/2009	7,943,664	17/05/2011
A813/2222	humanised anti-IL-25 antibody	National Phase	Application	Montenegro	P-2015-78	18/06/2015		
A813/2222	humanised anti-IL-25 antibody	National Phase	Application	Canada	2,759,050	30/09/2009		
A813/2222	humanised anti-IL-25 antibody	National Phase	Application	Brazil	PI 09190627	30/09/2009		
A813/2222	humanised anti-IL-25 antibody	National Phase	Application	India	2671/DELNP/2001	30/09/2009		
A813/2222	humanised anti-IL-25 antibody	National Phase	Application	New Zealand	592274	30/09/2009	592274	11/12/2012
A813/2222	humanised anti-IL-25 antibody	National Phase	Application	Australia	2009299465	30/09/2009		
A813/2222	humanised anti-IL-25 antibody	National Phase	Application	South Korea	10-2011-7009937	30/09/2009	101659452	19/09/2016
A813/2222	humanised anti-IL-25 antibody	National Phase	Application	Hong Kong	11108280.3	30/09/2009	HK11154022	02/10/2015
A813/2222	humanised anti-IL-25 antibody	National Phase	Application	Mexico	MX/a/2011/000395	30/09/2009	319011	03/04/2014
A813/2222	humanised anti-IL-25 antibody	National Phase	Application	Singapore	201102196-7	30/09/2009	169849	16/10/2013
A813/2222	humanised anti-IL-25 antibody	National Phase	Application	China	200980147932.6	30/09/2009	ZL2009801479326	22/10/2014
A813/2222	humanised anti-IL-25 antibody	National Phase	Application	Europe	09795802.9	30/09/2009	2344538	25/02/2015
A813/2222	humanised anti-IL-25 antibody	National Phase	Application	Japan	2011-528454	30/09/2009	5719771	27/03/2015
A813/2222	humanised anti-IL-25 antibody	National Phase	Application	United States	13/121,896	30/09/2009	8,658,169	25/02/2014
A813/2234	Fluorocarbon emulsion stabilizing surfac	National Phase	Application	Europe	2007638615	07/08/2007		
A813/2234	Fluorocarbon emulsion stabilizing surfac	National Phase	Application	United States	12/310,048	07/08/2007	9,012,390	21/04/2015
A813/2296	AID Mutants	National Phase	Application	India	7514/DELNP/2011	05/04/2010		
A813/2296	AID Mutants	National Phase	Application	Canada	2,757,178	05/04/2010		
A813/2296	AID Mutants	National Phase	Application	Russia	2011144569	05/04/2010	2537264	27/12/2014
A813/2296	AID Mutants	National Phase	Application	Europe	10723293.6	05/04/2010	2414507	02/07/2014
A813/2296	AID Mutants	National Phase	Application	China	201080023311.X	05/04/2010	ZL	06/01/2016

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant number	Grant date
A813/2296	AID Mutants	National Phase	Application	Japan	502830/2012	05/04/2010	2010R0023311 X 5663566	23/01/2015
A813/2296	AID Mutants	National Phase	Application	Australia	2010230985	05/04/2010	2010230985	07/01/2016
A813/2296	AID Mutants	National Phase	Application	United States	13/262,187	05/04/2010	9683226	20/06/2017
A813/2476	Improved cytosponge	National Phase	Application	Canada	CA20102780621	11/11/2010		
A813/2476	Improved cytosponge	National Phase	Application	Hong Kong	13103252.2	15/03/2013		
A813/2476	Improved cytosponge	National Phase	Application	United States	13/509,035	10/05/2012		
A813/2476	Improved cytosponge	National Phase	Application	India	4165/DELNP/2012	11/11/2010		
A813/2476	Improved cytosponge	National Phase	Application	Japan	JP2012-638396	11/11/2010	JP5759473	05/08/2015
A813/2476	Improved cytosponge	National Phase	Application	Europe	10796447.0	11/11/2010	EP2498684	29/03/2017
A813/2476	Improved cytosponge	National Phase	Application	Australia	2010317794	11/11/2010	2010317794	15/01/2015
A813/2476	Improved cytosponge	National Phase	Application	China	201080061260.X	11/11/2010	CN102711628	25/03/2015
A813/2479	TFE3 Barrett's biomarker	National Phase	Application	United States	12/833,548	09/07/2010 11:29	8709796	29/04/2014
A813/2499	genetic encoding of ubiquitination	National Phase	Application	Europe	11715594.5	23/03/2011		
A813/2661	Guanabenz analogues against GADD34	National Phase	Application	United States	14/760,350	10/01/2014	14/760,350	02/11/2016
A813/2661	Guanabenz analogues against GADD34	National Phase	Application	Canada	2,896,976	10/01/2014		
A813/2661	Guanabenz analogues against GADD34	National Phase	Divisional	Europe	16172393.8	10/01/2014		
A813/2661	Guanabenz analogues against GADD34	National Phase	Application	Brazil	BR 11 2015 016433 1	10/01/2014		
A813/2661	Guanabenz analogues against GADD34	National Phase	Application	Russia	RU2015 127827	10/01/2014		
A813/2661	Guanabenz analogues against GADD34	National Phase	Application	India	5769/DELNP/2015	10/01/2014		
A813/2661	Guanabenz analogues against GADD34	National Phase	Application	Mexico	MX/a/2015/00897 7	10/01/2014		
A813/2661	Clearing misfolded proteins (GADD34)	National Phase	Application	United Kingdom	1300435.3	10/01/2013		

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant number	Grant date
A813/2661	Guanabenz analogues against GADD34	National Phase	Application	South Korea	10-2015-7019864	10/01/2014		
A813/2661	Guanabenz analogues against GADD34	National Phase	Application	China	201480004604.1	10/01/2014		
A813/2661	Guanabenz analogues against GADD34	National Phase	Application	Israel	239629	10/01/2014		
A813/2661	Guanabenz analogues against GADD34	National Phase	Application	Japan	JP2015-552030	10/01/2014		
A813/2661	Guanabenz analogues against GADD34	National Phase	Application	Europe	14700310.7	10/01/2014	2943467	13/07/2016
A813/2661	Guanabenz analogues against GADD34	National Phase	Application	Australia	2014204831	10/01/2014		
A813/2707	Cyresponse for use in detecting H.pylori infection	National Phase	Application	Europe	12809298.8	22/11/2012		
A813/2743	Ubiquitin chain sequencing method	National Phase	Application	Europe	12766385.4	24/09/2012		
A813/2743	Ubiquitin chain sequencing method	National Phase	Application	United States	14/346,284	20/03/2014	9587265	07/03/2017
A813/2749	Method for detecting and counting DNA or protein molecules	National Phase	Application	Canada	2907868	09/04/2014		
A813/2749	Method for detecting and counting DNA or protein molecules	National Phase	Divisional	Europe	14194399.3	09/04/2014		
A813/2749	Method for detecting and counting DNA or protein molecules	National Phase	Application	United States	14782,654	06/10/2015		
A813/2749	Method for detecting and counting DNA or protein molecules	National Phase	Application	Brazil	BR 11 2015 025762 3	09/04/2014		
A813/2749	Method for detecting and counting DNA or protein molecules	National Phase	Application	China	201480020429	09/04/2014		
A813/2749	Method for detecting and counting DNA or protein molecules	National Phase	Application	China	201480020411.5	09/04/2014		
A813/2749	Method for detecting and counting DNA or protein molecules	National Phase	Application	Europe	14718146.1	07/12/2015	2828409	14/10/2015
A813/2749	Method for detecting and counting DNA or protein molecules	National Phase	Application	South Korea	10-2015-7032056	09/04/2014		
A813/2749	Method for detecting and counting DNA or protein molecules	National Phase	Application	United States	14782,650	06/10/2015		

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant number	Grant date
A813/2749	Method for detecting and counting DNA or protein molecules	National Phase	Application	Brazil	BR 11 2015 025763 1	09/04/2014		
A813/2749	Method for detecting and counting DNA or protein molecules	National Phase	Application	Canada	2907865	09/04/2014		
A813/2749	Method for detecting and counting DNA or protein molecules	National Phase	Application	Europe	14718147.3	09/04/2014	EP2828408	14/10/2015
A813/2749	Method for detecting and counting DNA or protein molecules	National Phase	Application	Australia	2014252805	16/10/2014		
A813/2749	Method for detecting and counting DNA or protein molecules	National Phase	Application	Australia	2014252804	16/10/2014		
A813/2855	Stabilised silicate compositions	National Phase	Application	United States	15/119071	13/02/2015		
A813/2855	Stabilised silicate compositions	National Phase	Application	Japan	2016-551833	13/02/2015		
A813/2855	Stabilised silicate compositions	National Phase	Application	Singapore	11201606656Q	13/02/2015		
A813/2855	Stabilised silicate compositions	National Phase	Application	Hong Kong	16114700.4	13/02/2015		
A813/2855	Stabilised silicate compositions	National Phase	Application	India	201627027697	13/02/2015		
A813/2855	Stabilised silicate compositions	National Phase	Application	South Korea	10-2016-7024827	13/02/2015		
A813/2855	Stabilised silicate compositions	National Phase	Application	Australia	2015216711	13/02/2015		
A813/2855	Stabilised silicate compositions	National Phase	Application	Eurasia	201691441	13/02/2015		
A813/2855	Stabilised silicate compositions	National Phase	Application	New Zealand	723746	13/02/2015		
A813/2855	Stabilised silicate compositions	National Phase	Application	Canada	2939419	13/02/2015		
A813/2855	Stabilised silicate compositions	National Phase	Application	Europe	15707169.7	13/02/2015		
A813/2855	Stabilised silicate compositions	National Phase	Application	China	201560018382.3	13/02/2015		
A813/2899	Method for producing gold EM grids	National Phase	Application	South Africa	2016/00920	12/08/2014		
A813/2899	Method for producing gold EM grids	National Phase	Application	Israel	243890	12/08/2014		
A813/2899	Method for producing gold EM grids	National Phase	Application	Japan	2016-533951	12/06/2014		
A813/2899	Method for producing gold EM grids	National Phase	Application	Singapore	11201600771U	12/08/2014		
A813/2899	Method for producing gold EM grids	National Phase	Application	Hong Kong	16112904.2	12/08/2014		

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant number	Grant date
A813/2899	Method for producing gold EM grids	National Phase	Application	United States	14/911,723	12/08/2014		
A813/2899	Method for producing gold EM grids	National Phase	Application	Australia	2014307715	12/08/2014		
A813/2899	Method for producing gold EM grids	National Phase	Application	Canada	2,919,961	12/08/2014		
A813/2899	Method for producing gold EM grids	National Phase	Application	Europe	14750632.3	12/08/2014		
A813/2899	Method for producing gold EM grids	National Phase	Application	China	201480049902.2	12/05/2014		
A813/2913	Thermostabilised version of SERT in a cocaine-bound confirmation	National Phase	Application	United States	14776908	13/03/2014		
A813/2913	Thermostabilised version of SERT in a cocaine-bound confirmation	National Phase	Application	Europe	14713889.5	13/03/2014		
A813/3217	Narcoleptics for T cell activation - part 2	PCT	Application	PCT	PCT/EP2017/0701 83	09/08/2017		
A813/3266	Sugar modified pro-drugs as senolytics	Priority	Application	United Kingdom	1708453.3	26/05/2017		
A813/3267	Compounds as senolytics	Priority	Application	United Kingdom	1708456.7	26/05/2017		
A813/355	MASP-2	National Phase	Application	United States	11032149	11/01/2005	7060267	13/06/2006
A813/355	MASP-2	National Phase	Application	United States	13359348	26/01/2012	8551790	08/10/2013
A813/355	MASP-2	National Phase	Application	United States	09/874,198	04/06/2001	6,959,601	29/11/2005
A813/355	MASP-2	National Phase	Application	United States	14031377	19/09/2013	9441262	13/09/2016
A813/355	MASP-2	National Phase	Application	United States	09874238	04/06/2001		
A813/355	MASP-2	National Phase	Application	United States	15227479	03/09/2016		
A813/355	MASP-2	National Phase	Provisional	United States	60042678	03/04/2007		
A813/930	Winter HLibrary Construction	National Phase	Application	Europe	90909224.9	16/05/1990	0425661	11/10/2000
A813/930	Winter HLibrary Construction	National Phase	Application	United States	07796,805	25/11/1991		
A813/930	Winter HLibrary Construction	National Phase	Continuation	United States	07/941,761	25/11/1992	6,291,160	18/09/2001

Ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant number	Grant date
A813/930	Winter II/Library Construction	National Phase	Divisional	United States	09726,653	28/11/2000	6,660,192	01/01/1900
A813/930	Winter II/Library Construction	National Phase	Application	United Kingdom	8909217.5	22/04/1989		
A813/930	Winter II/Library Construction	National Phase	Application	Japan	1-511700	13/11/1989	2919690	23/04/1999
A813/930	Winter II/Library Construction	National Phase	Application	Australia	45201/89	13/11/1989	634186	11/06/1993
A813/930	Winter II/Library Construction	National Phase	Application	Europe	89311731.7	13/11/1989	0368684	09/03/1994
A813/930	Winter II/Library Construction	National Phase	Application	Denmark	1647/90	13/11/1989	DK175392	20/09/2004
A813/930	Winter II/Library Construction	National Phase	Application	South Korea	701475/1990	13/11/1989	0194860	01/04/1999
A813/930	Winter II/Library Construction	National Phase	Application	Canada	1989-2002868.6	14/11/1989	2,002,868	20/03/2007
A813/930	Winter II/Library Construction	National Phase	Divisional	United States	09726,649	28/11/2000	6,969,586	29/11/2005
A813/930	Winter II/Library Construction	National Phase	Application	Europe	90908744.7	16/05/1990	0472638	11/10/2000
A813/930	Winter II/Library Construction	National Phase	Continuation	United States	09722,364	28/11/2000	6,545,142	08/04/2003
A813/930	Winter II/Library Construction	National Phase	Divisional	United States	08470,031	13/11/1989	6,248,516	19/06/2001
A813/930	Winter II/Library Construction	National Phase	Continuation	United States	07941,762	04/09/1992	6,291,161	18/09/2001
A813/930	Winter II/Library Construction	National Phase	Continuation	United States	07933,959	21/08/1992	6,291,159	18/09/2001
A813/930	Winter II/Library Construction	National Phase	Continuation	United States	07933,958	21/08/1992	6,291,156	18/09/2001

Part C - Other third party managed

Asset rel	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant number	Grant date
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	South Korea	2012-7027973	30/03/2011		
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	Ecuador	EC2012SPI2202	01/10/2012		
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	Europe	11763357.8	30/03/2011		
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	Singapore	20120070249	30/03/2011		
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	Japan	2013-0502790	30/03/2011		
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	New Zealand	2011-0802720	30/03/2011		
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	Hong Kong	20130112430	05/11/2013		
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	Ukraine	20120012980	30/03/2011		
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	Chile	20120002745	30/03/2011		
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	China	201180016673.0	30/03/2011		
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	Mexico	2012-0011479	30/03/2011		
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	Australia	2011-235232	30/03/2011	AU2011235232	21/05/2015
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	Costa Rica	20120553	30/10/2012		
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	Eurasia	20120090977	30/03/2011		
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	Peru	20120001830	30/03/2011		
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	Brazil	112012024786	30/03/2011		
A813/2543	Centocor IL-25 Antibodies 2	National Phase	Application	Canada	2011-2795043	30/03/2011		
A813/2741	Kis/Kid - Part2	National Phase	Application	Europe	12775131.1	17/09/2012		
A813/2741	Kis/Kid - Part2	National Phase	Application	United States	14/345.138	17/09/2012		
A813/3089	bi specific peptide	National Phase	Application	Europe	15807980.6	01/12/2015		
A813/3280	Anti-viral engineered antibodies	PCT	Application	United States	62307637	14/03/2016		
A813/3280	Anti-viral engineered antibodies	PCT	Application	PCT	PCT/US2017/022225	14/03/2017		
A813/3282	Cell Penetrating Peptides for SMA	PCT	Application	PCT	PCT/GB2018/050423	16/02/2018		

Asset ref	Title	Asset status	Filing type	Country	Filing number	Filing date	Grant number	Grant date
A813/3282	Cell Penetrating Peptides for SMA	PCT	Application	United Kingdom	1802588.1	16/02/2018		

46617.4
Classification: Confidential

54

WORK\31069583\3

Part D -- EP Designations

Ref	Title	Grant number	Country
A813/1486	Optical Sorting Method	DIV1522581	Italy
A813/1488	Optical Sorting Method	DIV1522581	NL
A813/1488	Optical Sorting Method	DIV1522581	Spain
A813/1488	Optical Sorting Method	DIV1522581	Sweden
A813/1486	Optical Sorting Method	DIV1522581	GB
A813/1488	Optical Sorting Method	DIV1905828	France
A813/1488	Optical Sorting Method	DIV1905828	Germany
A813/1488	Optical Sorting Method	DIV1905828	Italy
A813/1488	Optical Sorting Method	DIV1905828	NL
A813/1488	Optical Sorting Method	DIV1905828	Spain
A813/1488	Optical Sorting Method	DIV1905828	GB
A813/1488	Optical Sorting Method	EP1141272	Belgium
A813/1488	Optical Sorting Method	EP1141272	Denmark
A813/1488	Optical Sorting Method	EP1141272	France
A813/1488	Optical Sorting Method	EP1141272	Germany
A813/1488	Optical Sorting Method	EP1141272	Italy
A813/1488	Optical Sorting Method	EP1141272	NL
A813/1488	Optical Sorting Method	EP1141272	Spain
A813/1488	Optical Sorting Method	EP1141272	Sweden
A813/1488	Optical Sorting Method	EP1141272	Switz/Liechtenstein
A813/1488	Optical Sorting Method	EP1141272	GB
A813/1490	Intracellular Selection	EP1166121	France
A813/1490	Intracellular Selection	EP1166121	Germany
A813/1490	Intracellular Selection	EP1166121	Italy
A813/1490	Intracellular Selection	EP1166121	Spain
A813/1490	Intracellular Selection	EP1166121	GB
A813/1545	Directed Evolution Method	EP1317539	Belgium

Ref	Title	Grant number	Country
A813/1545	Directed Evolution Method	EP1317539	Denmark
A813/1545	Directed Evolution Method	EP1317539	France
A813/1545	Directed Evolution Method	EP1317539	Germany
A813/1545	Directed Evolution Method	EP1317539	Italy
A813/1545	Directed Evolution Method	EP1317539	NL
A813/1545	Directed Evolution Method	EP1317539	Spain
A813/1545	Directed Evolution Method	EP1317539	Sweden
A813/1545	Directed Evolution Method	EP1317539	Switz/Liechtenstein
A813/1545	Directed Evolution Method	EP1317539	GB
A813/1571	Linkers	EP1250424	Belgium
A813/1571	Linkers	EP1250424	France
A813/1571	Linkers	EP1250424	Germany
A813/1571	Linkers	EP1250424	Ireland
A813/1571	Linkers	EP1250424	Switz/Liechtenstein
A813/1571	Linkers	EP1250424	GB
A813/1627	Process for Producing Photocleavable Com	EP1377548	GB
A813/1673	Emulsion Compositions	EP1518937	Austria
A813/1673	Emulsion Compositions	EP1518937	Belgium
A813/1673	Emulsion Compositions	EP1518937	France
A813/1673	Emulsion Compositions	EP1518937	Germany
A813/1673	Emulsion Compositions	EP1518937	Ireland
A813/1673	Emulsion Compositions	EP1518937	Italy
A813/1673	Emulsion Compositions	EP1518937	Luxembourg
A813/1673	Emulsion Compositions	EP1518937	Monaco
A813/1673	Emulsion Compositions	EP1518937	Spain
A813/1673	Emulsion Compositions	EP1518937	Switz/Liechtenstein
A813/1673	Emulsion Compositions	EP1518937	GB
A813/1673	Emulsion Compositions	EP1446504	Belgium
A813/1673	Emulsion Compositions	EP1446504	Denmark

Ref	Title	Grant number	Country
A813/1673	Emulsion Compositions	EP1446504	France
A813/1673	Emulsion Compositions	EP1446504	Germany
A813/1673	Emulsion Compositions	EP1446504	Italy
A813/1673	Emulsion Compositions	EP1446504	NL
A813/1673	Emulsion Compositions	EP1446504	Spain
A813/1673	Emulsion Compositions	EP1446504	Sweden
A813/1673	Emulsion Compositions	EP1446504	Switz/Liechtenstein
A813/1673	Emulsion Compositions	EP1446504	GB
A813/1675	Molecules	EP1440083	Belgium
A813/1675	Molecules	EP1440083	Denmark
A813/1675	Molecules	EP1440083	France
A813/1675	Molecules	EP1440083	Germany
A813/1675	Molecules	EP1440083	Italy
A813/1675	Molecules	EP1440083	NL
A813/1675	Molecules	EP1440083	Spain
A813/1675	Molecules	EP1440083	Sweden
A813/1675	Molecules	EP1440083	Switz/Liechtenstein
A813/1675	Molecules	EP1440083	GB
A813/1678	Crystal Structure	EP 1172374	GB
A813/1708	Activation induced Deaminase (Aid)	EP 1506288	AT
A813/1708	Activation induced Deaminase (Aid)	EP 1506288	BE
A813/1708	Activation induced Deaminase (Aid)	EP 1506288	CH
A813/1708	Activation induced Deaminase (Aid)	EP 1506288	DE
A813/1708	Activation induced Deaminase (Aid)	EP 1506288	DK
A813/1708	Activation induced Deaminase (Aid)	EP 1506288	ES
A813/1708	Activation induced Deaminase (Aid)	EP 1506288	FR
A813/1708	Activation induced Deaminase (Aid)	EP 1506288	GB
A813/1708	Activation induced Deaminase (Aid)	EP 1506288	IE
A813/1708	Activation induced Deaminase (Aid)	EP 1506288	IT

Ref	Title	Grant number	Country
A813/1708	Activation Induced Deaminase (AID)	EP 1506288	NL
A813/1708	Activation Induced Deaminase (AID)	EP 1506288	SE
A813/1791	CST Emulsions	EP 1680516	BE
A813/1791	CST Emulsions	EP 1680516	DK
A813/1791	CST Emulsions	EP 1680516	FR
A813/1791	CST Emulsions	EP 1680516	DE
A813/1791	CST Emulsions	EP 1680516	IT
A813/1791	CST Emulsions	EP 1680516	NL
A813/1791	CST Emulsions	EP 1680516	ES
A813/1791	CST Emulsions	EP 1680516	SE
A813/1791	CST Emulsions	EP 1680516	CH
A813/1791	CST Emulsions	EP 1680516	GB
A813/1792	FC Fusion	EP 1581559	BE
A813/1792	FC Fusion	EP 1581559	FR
A813/1792	FC Fusion	EP 1581559	DE
A813/1792	FC Fusion	EP 1581559	IT
A813/1792	FC Fusion	EP 1581559	ES
A813/1792	FC Fusion	EP 1581559	GB
A813/1798	GnRH conjugates	EP 1613357	DE
A813/1798	GnRH conjugates	EP 1613357	GB
A813/1804	Selection By Compartmentalised Screening	EP 1606976	FR
A813/1804	Selection By Compartmentalised Screening	EP 1606976	DE
A813/1804	Selection By Compartmentalised Screening	EP 1606976	CH
A813/1804	Selection By Compartmentalised Screening	EP 1606976	GB
A813/1810	M4 Emulsions	DIV 2145956	BE
A813/1810	M4 Emulsions	DIV 2145956	DK
A813/1810	M4 Emulsions	DIV 2145956	FR
A813/1810	M4 Emulsions	DIV 2145956	DE
A813/1810	M4 Emulsions	DIV 2145956	IT

Ref	Title	Grant number	Country
A813/1810	M4 Emulsions	DIV 2145956	NL
A813/1810	M4 Emulsions	DIV 2145956	ES
A813/1810	M4 Emulsions	DIV 2145956	SE
A813/1810	M4 Emulsions	DIV 2145956	CH
A813/1810	M4 Emulsions	DIV 2145956	GB
A813/1857	Method For Generating Diversity 2	EP 1399016	DK
A813/1857	Method For Generating Diversity 2	EP 1399016	FR
A813/1857	Method For Generating Diversity 2	EP 1399016	DE
A813/1857	Method For Generating Diversity 2	EP 1399016	IE
A813/1857	Method For Generating Diversity 2	EP 1399016	LU
A813/1857	Method For Generating Diversity 2	EP 1399016	CH
A813/1857	Method For Generating Diversity 2	EP 1399016	GB
A813/1897	Compartmentalised Screening	DIV 2602018	FR
A813/1897	Compartmentalised Screening	DIV 2602018	DE
A813/1897	Compartmentalised Screening	DIV 2602018	GB
A813/1897	Compartmentalised Screening	EP 1842067	CY
A813/1897	Compartmentalised Screening	EP 1842067	FR
A813/1897	Compartmentalised Screening	EP 1842067	DE
A813/1897	Compartmentalised Screening	EP 1842067	HU
A813/1897	Compartmentalised Screening	EP 1842067	IE
A813/1897	Compartmentalised Screening	EP 1842067	LU
A813/1897	Compartmentalised Screening	EP 1842067	MC
A813/1897	Compartmentalised Screening	EP 1842067	SI
A813/1897	Compartmentalised Screening	EP 1842067	CH
A813/1897	Compartmentalised Screening	EP 1842067	TR
A813/1897	Compartmentalised Screening	EP 1842067	GB
A813/1900	Directed Evolution of Nucleic Acids	DIV 2267163	FR
A813/1900	Directed Evolution of Nucleic Acids	DIV 2267163	DE
A813/1900	Directed Evolution of Nucleic Acids	DIV 2267163	GB

WORK\31069583\3

Ref.	Title	Grant number	Country
A813/1900	Directed Evolution of Nucleic Acids	EP 1805324	FR
A813/1900	Directed Evolution of Nucleic Acids	EP 1805324	DE
A813/1900	Directed Evolution of Nucleic Acids	EP 1805324	GB
A813/1900	Directed Evolution of Nucleic Acids	DIV 2270236	FR
A813/1900	Directed Evolution of Nucleic Acids	DIV 2270236	DE
A813/1900	Directed Evolution of Nucleic Acids	DIV 2270236	GB
A813/1900	Directed Evolution of Nucleic Acids	DIV 2270235	FR
A813/1900	Directed Evolution of Nucleic Acids	DIV 2270335	DE
A813/1900	Directed Evolution of Nucleic Acids	DIV 2270235	GB
A813/1969	E10 Polymerase	EP 2074211	BE
A813/1969	E10 Polymerase	EP 2074211	DK
A813/1969	E10 Polymerase	EP 2074211	FR
A813/1969	E10 Polymerase	EP 2074211	DE
A813/1969	E10 Polymerase	EP 2074211	IT
A813/1969	E10 Polymerase	EP 2074211	NL
A813/1969	E10 Polymerase	EP 2074211	ES
A813/1969	E10 Polymerase	EP 2074211	SE
A813/1969	E10 Polymerase	EP 2074211	CH
A813/1969	E10 Polymerase	EP 2074211	GB
A813/1985	Zinc Fingers	EP 1974034	FR
A813/1985	Zinc Fingers	EP 1974034	GB
A813/2002	HU1 Polymerase	EP 2076592	BE
A813/2002	HU1 Polymerase	EP 2076592	DK
A813/2002	HU1 Polymerase	EP 2076592	FR
A813/2002	HU1 Polymerase	EP 2076592	DE
A813/2002	HU1 Polymerase	EP 2076592	HU
A813/2002	HU1 Polymerase	EP 2076592	IE
A813/2002	HU1 Polymerase	EP 2076592	IT
A813/2002	HU1 Polymerase	EP 2076592	LU

WORK/31069583v.3

Ref	Title	Grant number	Country
A813/2002	HU1 Polymerase	EP 2076592	MT
A813/2002	HU1 Polymerase	EP 2076592	MC
A813/2002	HU1 Polymerase	EP 2076592	NL
A813/2002	HU1 Polymerase	EP 2076592	PT
A813/2002	HU1 Polymerase	EP 2076592	ES
A813/2002	HU1 Polymerase	EP 2076592	SE
A813/2002	HU1 Polymerase	EP 2076592	CH
A813/2002	HU1 Polymerase	EP 2076592	GB
A813/2007	Nitric Oxide Donors (Mitosno)	EP 2066680	AT
A813/2007	Nitric Oxide Donors (Mitosno)	EP 2066680	BE
A813/2007	Nitric Oxide Donors (Mitosno)	EP 2066680	DK
A813/2007	Nitric Oxide Donors (Mitosno)	EP 2066680	FR
A813/2007	Nitric Oxide Donors (Mitosno)	EP 2066680	DE
A813/2007	Nitric Oxide Donors (Mitosno)	EP 2066680	IE
A813/2007	Nitric Oxide Donors (Mitosno)	EP 2066680	IT
A813/2007	Nitric Oxide Donors (Mitosno)	EP 2066680	NL
A813/2007	Nitric Oxide Donors (Mitosno)	EP 2066680	ES
A813/2007	Nitric Oxide Donors (Mitosno)	EP 2066680	SE
A813/2007	Nitric Oxide Donors (Mitosno)	EP 2066680	CH
A813/2007	Nitric Oxide Donors (Mitosno)	EP 2066680	GB
A813/2010	Deubiquitylating enzyme - trabid	EP 2021471	FR
A813/2010	Deubiquitylating enzyme - trabid	EP 2021471	DE
A813/2010	Deubiquitylating enzyme - trabid	EP 2021471	IT
A813/2010	Deubiquitylating enzyme - trabid	EP 2021471	GB
A813/2012	Mineral Precipitation Technique	EP 2125847	AT
A813/2012	Mineral Precipitation Technique	EP 2125847	BE
A813/2012	Mineral Precipitation Technique	EP 2125847	BG
A813/2012	Mineral Precipitation Technique	EP 2125847	HR
A813/2012	Mineral Precipitation Technique	EP 2125847	CY

Ref	Title	Grant number	Country
A813/2012	Mineral Precipitation Technique	EP 2125847	CZ
A813/2012	Mineral Precipitation Technique	EP 2125847	DK
A813/2012	Mineral Precipitation Technique	EP 2125847	EE
A813/2012	Mineral Precipitation Technique	EP 2125847	FI
A813/2012	Mineral Precipitation Technique	EP 2125847	FR
A813/2012	Mineral Precipitation Technique	EP 2125847	DE
A813/2012	Mineral Precipitation Technique	EP 2125847	GR
A813/2012	Mineral Precipitation Technique	EP 2125847	HU
A813/2012	Mineral Precipitation Technique	EP 2125847	IS
A813/2012	Mineral Precipitation Technique	EP 2125847	IE
A813/2012	Mineral Precipitation Technique	EP 2125847	IT
A813/2012	Mineral Precipitation Technique	EP 2125847	LV
A813/2012	Mineral Precipitation Technique	EP 2125847	LT
A813/2012	Mineral Precipitation Technique	EP 2125847	LU
A813/2012	Mineral Precipitation Technique	EP 2125847	MT
A813/2012	Mineral Precipitation Technique	EP 2125847	MC
A813/2012	Mineral Precipitation Technique	EP 2125847	NL
A813/2012	Mineral Precipitation Technique	EP 2125847	NO
A813/2012	Mineral Precipitation Technique	EP 2125847	PL
A813/2012	Mineral Precipitation Technique	EP 2125847	PT
A813/2012	Mineral Precipitation Technique	EP 2125847	RO
A813/2012	Mineral Precipitation Technique	EP 2125847	SK
A813/2012	Mineral Precipitation Technique	EP 2125847	SI
A813/2012	Mineral Precipitation Technique	EP 2125847	ES
A813/2012	Mineral Precipitation Technique	EP 2125847	SE
A813/2012	Mineral Precipitation Technique	EP 2125847	CH
A813/2012	Mineral Precipitation Technique	EP 2125847	TR
A813/2012	Mineral Precipitation Technique	EP 2125847	GB
A813/204B	IL-25 Ab against allergic reactions	EP 2144934	AT

Ref	Title	Grant number	Country
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	BE
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	BG
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	HR
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	CY
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	CZ
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	DK
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	EE
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	FI
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	FR
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	DE
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	GR
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	HU
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	IS
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	IE
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	IT
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	LV
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	LT
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	LU
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	MC
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	NL
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	NO
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	PL
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	PT
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	RO
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	SK
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	SI
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	ES
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	SE
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	CH

Ref	Title	Grant number	Country
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	TR
A813/2048	IL-25 Ab against allergic reactions	EP 2144934	GB
A813/2139	Humanised AP33 - MRCT10	EP 2231704	GB
A813/2213	Phosphate Binder	EP 2320884	AT
A813/2213	Phosphate Binder	EP 2320884	BE
A813/2213	Phosphate Binder	EP 2320884	BG
A813/2213	Phosphate Binder	EP 2320884	HR
A813/2213	Phosphate Binder	EP 2320884	CY
A813/2213	Phosphate Binder	EP 2320884	CZ
A813/2213	Phosphate Binder	EP 2320884	DK
A813/2213	Phosphate Binder	EP 2320884	EE
A813/2213	Phosphate Binder	EP 2320884	FI
A813/2213	Phosphate Binder	EP 2320884	FR
A813/2213	Phosphate Binder	EP 2320884	DE
A813/2213	Phosphate Binder	EP 2320884	GR
A813/2213	Phosphate Binder	EP 2320884	HU
A813/2213	Phosphate Binder	EP 2320884	IS
A813/2213	Phosphate Binder	EP 2320884	IE
A813/2213	Phosphate Binder	EP 2320884	IT
A813/2213	Phosphate Binder	EP 2320884	LV
A813/2213	Phosphate Binder	EP 2320884	LT
A813/2213	Phosphate Binder	EP 2320884	LU
A813/2213	Phosphate Binder	EP 2320884	MC
A813/2213	Phosphate Binder	EP 2320884	NL
A813/2213	Phosphate Binder	EP 2320884	NO
A813/2213	Phosphate Binder	EP 2320884	PL
A813/2213	Phosphate Binder	EP 2320884	PT
A813/2213	Phosphate Binder	EP 2320884	RO
A813/2213	Phosphate Binder	EP 2320884	SM

Ref	Title	Grant number	Country
A813/2213	Phosphate Binder	EP 2320884	SK
A813/2213	Phosphate Binder	EP 2320884	SI
A813/2213	Phosphate Binder	EP 2320884	ES
A813/2213	Phosphate Binder	EP 2320884	SE
A813/2213	Phosphate Binder	EP 2320884	CH
A813/2213	Phosphate Binder	EP 2320884	TR
A813/2213	Phosphate Binder	EP 2320884	GB
A813/2222	humanised anti-IL25 antibody	EP2344538	Albania
A813/2222	humanised anti-IL25 antibody	EP2344538	Austria
A813/2222	humanised anti-IL25 antibody	EP2344538	Bosnia & Herzegovina
A813/2222	humanised anti-IL25 antibody	EP2344538	Belgium
A813/2222	humanised anti-IL25 antibody	EP2344538	Bulgaria
A813/2222	humanised anti-IL25 antibody	EP2344538	Switzerland/Liechtenstein
A813/2222	humanised anti-IL25 antibody	EP2344538	Cyprus
A813/2222	humanised anti-IL25 antibody	EP2344538	Czech Republic
A813/2222	humanised anti-IL25 antibody	EP2344538	Germany
A813/2222	humanised anti-IL25 antibody	EP2344538	Denmark
A813/2222	humanised anti-IL25 antibody	EP2344538	Estonia
A813/2222	humanised anti-IL25 antibody	EP2344538	Spain
A813/2222	humanised anti-IL25 antibody	EP2344538	Finland
A813/2222	humanised anti-IL25 antibody	EP2344538	France
A813/2222	humanised anti-IL25 antibody	EP2344538	United Kingdom
A813/2222	humanised anti-IL25 antibody	EP2344538	Greece
A813/2222	humanised anti-IL25 antibody	EP2344538	Croatia
A813/2222	humanised anti-IL25 antibody	EP2344538	Hungary
A813/2222	humanised anti-IL25 antibody	EP2344538	Ireland
A813/2222	humanised anti-IL25 antibody	EP2344538	Iceland
A813/2222	humanised anti-IL25 antibody	EP2344538	Italy
A813/2222	humanised anti-IL25 antibody	EP2344538	Lithuania

Ref	Title	Grant number	Country
A813/2222	humanised anti-IL25 antibody	EP2344538	Luxembourg
A813/2222	humanised anti-IL25 antibody	EP2344538	Latvia
A813/2222	humanised anti-IL25 antibody	EP2344538	Monaco
A813/2222	humanised anti-IL25 antibody	EP2344538	Macedonia
A813/2222	humanised anti-IL25 antibody	EP2344538	Malta
A813/2222	humanised anti-IL25 antibody	EP2344538	Netherlands
A813/2222	humanised anti-IL25 antibody	EP2344538	Norway
A813/2222	humanised anti-IL25 antibody	EP2344538	Poland
A813/2222	humanised anti-IL25 antibody	EP2344538	Portugal
A813/2222	humanised anti-IL25 antibody	EP2344538	Romania
A813/2222	humanised anti-IL25 antibody	EP2344538	Serbia
A813/2222	humanised anti-IL25 antibody	EP2344538	Sweden
A813/2222	humanised anti-IL25 antibody	EP2344538	Slovenia
A813/2222	humanised anti-IL25 antibody	EP2344538	Slovak Republic
A813/2222	humanised anti-IL25 antibody	EP2344538	San Marino
A813/2222	humanised anti-IL25 antibody	EP2344538	Turkey
A813/2261	anti-IL-25 receptor antibodies	EP2417161	Austria
A813/2261	anti-IL-25 receptor antibodies	EP2417161	Belgium
A813/2261	anti-IL-25 receptor antibodies	EP2417161	Denmark
A813/2261	anti-IL-25 receptor antibodies	EP2417161	France
A813/2261	anti-IL-25 receptor antibodies	EP2417161	Germany
A813/2261	anti-IL-25 receptor antibodies	EP2417161	Iceland
A813/2261	anti-IL-25 receptor antibodies	EP2417161	Ireland
A813/2261	anti-IL-25 receptor antibodies	EP2417161	Italy
A813/2261	anti-IL-25 receptor antibodies	EP2417161	Luxembourg
A813/2261	anti-IL-25 receptor antibodies	EP2417161	Netherlands
A813/2261	anti-IL-25 receptor antibodies	EP2417161	Norway
A813/2261	anti-IL-25 receptor antibodies	EP2417161	Spain
A813/2261	anti-IL-25 receptor antibodies	EP2417161	Sweden

Ref	Title	Grant number	Country
A813/2261	anti-IL-25 receptor antibodies	EP2417161	Switzerland/Liechtenstein
A813/2261	anti-IL-25 receptor antibodies	EP2417161	United Kingdom
A813/2265	Gadolinium-tagged liposome contrast agent	EP2501415	Belgium
A813/2265	Gadolinium-tagged liposome contrast agent	EP2501415	Denmark
A813/2265	Gadolinium-tagged liposome contrast agent	EP2501415	France
A813/2265	Gadolinium-tagged liposome contrast agent	EP2501415	Germany
A813/2265	Gadolinium-tagged liposome contrast agent	EP2501415	Italy
A813/2265	Gadolinium-tagged liposome contrast agent	EP2501415	Luxembourg
A813/2265	Gadolinium-tagged liposome contrast agent	EP2501415	Netherlands
A813/2265	Gadolinium-tagged liposome contrast agent	EP2501415	Spain
A813/2265	Gadolinium-tagged liposome contrast agent	EP2501415	Sweden
A813/2265	Gadolinium-tagged liposome contrast agent	EP2501415	United Kingdom
A813/2291	Predictive use of CpG methylation	EP2391730	Switzerland
A813/2291	Predictive use of CpG methylation	EP2391730	Germany
A813/2291	Predictive use of CpG methylation	EP2391730	France
A813/2291	Predictive use of CpG methylation	EP2391730	United Kingdom
A813/2296	AID Mutants	EP2414507	Denmark
A813/2296	AID Mutants	EP2414507	France
A813/2296	AID Mutants	EP2414507	Germany
A813/2296	AID Mutants	EP2414507	Ireland
A813/2296	AID Mutants	EP2414507	Italy
A813/2296	AID Mutants	EP2414507	Netherlands
A813/2296	AID Mutants	EP2414507	Spain
A813/2296	AID Mutants	EP2414507	Switzerland/Liechtenstein
A813/2296	AID Mutants	EP2414507	United Kingdom
A813/2404	Oesophageal prognostic signature	EP2550534	France
A813/2404	Oesophageal prognostic signature	EP2550534	Germany
A813/2404	Oesophageal prognostic signature	EP2550534	United Kingdom
A813/2476	Improved cyrospunge	EP2498684	Germany

Ref	Title	Grant number	Country
A813/2476	Improved cytosporige	EP2498684	France
A813/2476	Improved cytosporige	EP2498684	United Kingdom
A813/2566	Mineral oxide Oxygen sensors	EP2668495	France
A813/2566	Mineral oxide Oxygen sensors	EP2668495	Germany
A813/2566	Mineral oxide Oxygen sensors	EP2668495	Ireland
A813/2566	Mineral oxide Oxygen sensors	EP2668495	Switzerland/Liechtenstein
A813/2566	Mineral oxide Oxygen sensors	EP2668495	United Kingdom
A813/2661	Guanabenz analogues against GADD34	EP2943467	Austria
A813/2661	Guanabenz analogues against GADD34	EP2943467	Belgium
A813/2661	Guanabenz analogues against GADD34	EP2943467	Bulgaria
A813/2661	Guanabenz analogues against GADD34	EP2943467	Croatia
A813/2661	Guanabenz analogues against GADD34	EP2943467	Czech Republic
A813/2661	Guanabenz analogues against GADD34	EP2943467	Denmark
A813/2661	Guanabenz analogues against GADD34	EP2943467	Estonia
A813/2661	Guanabenz analogues against GADD34	EP2943467	Finland
A813/2661	Guanabenz analogues against GADD34	EP2943467	France
A813/2661	Guanabenz analogues against GADD34	EP2943467	Germany
A813/2661	Guanabenz analogues against GADD34	EP2943467	Greece
A813/2661	Guanabenz analogues against GADD34	EP2943467	Hungary
A813/2661	Guanabenz analogues against GADD34	EP2943467	Iceland
A813/2661	Guanabenz analogues against GADD34	EP2943467	Ireland
A813/2661	Guanabenz analogues against GADD34	EP2943467	Italy
A813/2661	Guanabenz analogues against GADD34	EP2943467	Latvia
A813/2661	Guanabenz analogues against GADD34	EP2943467	Switzerland/Liechtenstein
A813/2661	Guanabenz analogues against GADD34	EP2943467	Lithuania
A813/2661	Guanabenz analogues against GADD34	EP2943467	Luxembourg
A813/2661	Guanabenz analogues against GADD34	EP2943467	Netherlands
A813/2661	Guanabenz analogues against GADD34	EP2943467	Norway
A813/2661	Guanabenz analogues against GADD34	EP2943467	Poland

Ref	Title	Grant number	Country
A813/2661	Guanabenz analogues against GADD34	EP2943467	Portugal
A813/2661	Guanabenz analogues against GADD34	EP2943467	Romania
A813/2661	Guanabenz analogues against GADD34	EP2943467	Serbia
A813/2661	Guanabenz analogues against GADD34	EP2943467	Slovak Republic
A813/2661	Guanabenz analogues against GADD34	EP2943467	Slovenia
A813/2661	Guanabenz analogues against GADD34	EP2943467	Spain
A813/2661	Guanabenz analogues against GADD34	EP2943467	Sweden
A813/2661	Guanabenz analogues against GADD34	EP2943467	Turkey
A813/2661	Guanabenz analogues against GADD34	EP2943467	United Kingdom
A813/2749	Method for detecting and counting DNA or protein molecules	EP2828409	Belgium
A813/2749	Method for detecting and counting DNA or protein molecules	EP2828409	Switzerland/Liechtenstein
A813/2749	Method for detecting and counting DNA or protein molecules	EP2828409	Germany
A813/2749	Method for detecting and counting DNA or protein molecules	EP2828409	Denmark
A813/2749	Method for detecting and counting DNA or protein molecules	EP2828409	Spain
A813/2749	Method for detecting and counting DNA or protein molecules	EP2828409	Finland
A813/2749	Method for detecting and counting DNA or protein molecules	EP2828409	France
A813/2749	Method for detecting and counting DNA or protein molecules	EP2828409	United Kingdom
A813/2749	Method for detecting and counting DNA or protein molecules	EP2828409	Ireland
A813/2749	Method for detecting and counting DNA or protein molecules	EP2828409	Italy
A813/2749	Method for detecting and counting DNA or protein molecules	EP2828409	Netherlands
A813/2749	Method for detecting and counting DNA or protein molecules	EP2828409	Sweden
A813/2749	Method for detecting and counting DNA or protein molecules	EP2828408	Belgium
A813/2749	Method for detecting and counting DNA or protein molecules	EP2828408	Switzerland/Liechtenstein
A813/2749	Method for detecting and counting DNA or protein molecules	EP2828408	Germany
A813/2749	Method for detecting and counting DNA or protein molecules	EP2828408	Denmark
A813/2749	Method for detecting and counting DNA or protein molecules	EP2828408	Spain
A813/2749	Method for detecting and counting DNA or protein molecules	EP2828408	Finland
A813/2749	Method for detecting and counting DNA or protein molecules	EP2828408	France
A813/2749	Method for detecting and counting DNA or protein molecules	EP2828408	United Kingdom

Ref	Title	Grant number	Country
A813/2749	Method for detecting and counting DNA or protein molecules	EP2828408	Ireland
A813/2749	Method for detecting and counting DNA or protein molecules	EP2828408	Italy
A813/2749	Method for detecting and counting DNA or protein molecules	EP2828408	Netherlands
A813/2749	Method for detecting and counting DNA or protein molecules	EP2828408	Sweden
A813/2765	Nonhomene Modified Peptides and their labelling ITH Tetrazine Compounds	EP2804872	Grant 21.03.18- countries not yet chosen
A813/2802	Rapid site-specific labelling of proteins, demonstrated by an alkyne cycloaddition	EP2852664	France
A813/2802	Rapid site-specific labelling of proteins, demonstrated by an alkyne cycloaddition	EP2852664	Germany
A813/2802	Rapid site-specific labelling of proteins, demonstrated by an alkyne cycloaddition	EP2852664	United Kingdom
A813/2808	Diagnosis of high grade dysplasia	EP2850208	France
A813/2808	Diagnosis of high grade dysplasia	EP2850208	Germany
A813/2808	Diagnosis of high grade dysplasia	EP2850208	United Kingdom

WORK\31069583.v.3

70

46617.4
Classification: Confidential

Schedule 2

TRADE MARKS

Asset ref	Title	Type	Country	Application number	Application date	Reg. number	Registered
A814/2477	Diagnostic sponge trademark	Trademark	UK	2537681	29/01/2010	2537681	29/01/2010
A814/2477	Diagnostic sponge trademark	Trademark	Int'l	1046086	01/07/2010	1046086	01/07/2010
A814/2477	Diagnostic sponge trademark	Trademark	AU	1046086	01/07/2010	1379555	27/01/2011
A814/2477	Diagnostic sponge trademark	Trademark	CTM (EP)	1046086	01/07/2010	1046086	26/06/2011
A814/2477	Diagnostic sponge trademark	Trademark	US	1046086	01/07/2010	4,014,523	23/08/2011
A814/2477	Diagnostic sponge trademark	Trademark	JP	1046086	01/07/2010	1046086	23/11/2011
A814/2477	Diagnostic sponge trademark	Trademark	CN	12146895	04/02/2013	12146895	28/07/2014
A814/3137	Diagnostic sponge trademark	Trademark	US	86465782	26/11/2014	4879736	05/01/2016
A814/3137	UltrAuFoil	Trademark	CTM (EP)	13496138	25/11/2015	13496138	27/04/2015
A814/3137	UltrAuFoil	Trademark	CA	1729579	22/05/2015	TMA960111	13/01/2017
A814/3137	UltrAuFoil	Trademark	Int'l	1256433	22/05/2015	1256433	22/05/2015
A814/3137	UltrAuFoil	Trademark	AU	1256433	22/05/2015	1707659	22/10/2015
A814/3137	UltrAuFoil	Trademark	CN	13496138	22/05/2015	1256433	10/05/2016
A814/3137	UltrAuFoil	Trademark	SG	1256433	22/05/2015	40201512326T	06/01/2016
A814/3137	UltrAuFoil	Trademark	KR	1256433	22/05/2015	1069985	17/03/2016
A814/3137	UltrAuFoil	Trademark	JP	1256433	22/05/2015	1256433	28/10/2016
A814/3137	UltrAuFoil	Trademark	IL	1256433	22/05/2015	1256433	02/03/2017
A814/3143	Morpheus	Trademark	UK	2639714	25/10/2012	2639714	15/02/2013
A814/3143	Morpheus	Trademark	US	4766762	19/04/2013	4766762	07/07/2015
A814/3143	Morpheus	Trademark	CTM (EP)	011623907	04/09/2013	11623907	29/07/2013
A814/3136	GrafFoil	Trademark	US	96465962	26/11/2014	4879737	05/01/2016
A814/3136	GrafFoil	Trademark	CTM (EP)	13496112	25/11/2014	13496112	27/04/2015
A814/3136	GrafFoil	Trademark	CA	1729578	25/05/2015	1729578	28/10/2016
A814/3136	GrafFoil	Trademark	Int'l	1256436	22/05/2015	1256436	22/05/2015

Asset ref	Title	Type	Country	Application number	Application date	Reg number	Registered
A814/3136	GraFoil	Trademark	AU	1256436	22/05/2015	1707861	22/10/2015
A814/3136	GraFoil	Trademark	CN	1256436	22/05/2015	G1256436	27/02/2017
A814/3136	GraFoil	Trademark	IL	1256436	22/05/2015	1256436	02/03/2017
A814/3136	GraFoil	Trademark	JP	1256436	22/05/2015	1256436	18/11/2016
A814/3136	GraFoil	Trademark	KR	1256436	22/05/2015	1059995	17/03/2016
A814/3136	GraFoil	Trademark	SG	1256436	22/05/2015	40201512327X	06/01/2016
A814/3007	Mousebook	Trademark	GB	2492984	17/07/2008	2492984	26/12/2008
A814/3007	Mousebook	Trademark	Int'l	UK108988	16/01/2009	992642	05/03/2009
A814/3007	Mousebook	Trademark	AU	1287853	16/01/2009	1287853	07/12/2009
A814/3007	Mousebook	Trademark	CN	UK108988	16/01/2009	G992642	19/07/2011
A814/3007	Mousebook	Trademark	EM	992642	16/01/2009	992642	05/03/2009
A814/3007	Mousebook	Trademark	IN	1774966	16/01/2009	1774966	26/11/2011
A814/3007	Mousebook	Trademark	US	7764993	15/01/2009	3902497	11/01/2011


Schedule 3

REGISTERED DESIGNS


Asset ref	Title	Type	Country	Application number	Application date	Reg number	Registered
A814/2836	Cryopuck	Design	EP	002593483-0001	09/12/2014	002593483-0001	11/12/2014
A814/2836	Cryopuck	Design	JP	2015-012779	09/06/2015	1542476	18/12/2015
A814/2836	Cryopuck	Design	AU	201512940	04/06/2015	362823	22/07/2015
A814/2836	Cryopuck	Design	CN	2.0153E+11	09/06/2015	ZL 201530185651.8	09/12/2015
A814/2836	Cryopuck	Design	CA	162857	08/06/2015	162857	25/01/2016
A814/2836	Cryopuck	Design	US	29/531136	23/06/2015		
A814/3279	Cryostat	Design	JP	2017-010717	19/05/2017		
A814/3279	Cryostat	Design	JP	2017-010718	19/05/2017		
A814/3279	Cryostat	Design	EP	004515468-0001	21/11/2017	004515468-0001	28/11/2017
A814/3279	Cryostat	Design	EP	004515468-0002	21/11/2017	004515468-0002	28/11/2017
A814/3279	Cryostat	Design	EP	004515468-0003	21/11/2017	004515468-0003	28/11/2017
A814/3279	Cryostat	Design	US	29/626922			

Executed as a deed by affixing the common seal of
The Medical Research Council


In the presence of:


.....


Authorised Signatory


.....

Authorised Signatory



Executed as a deed by affixing the common seal of
United Kingdom Research and Innovation



Member

In the presence of:

